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Circulating tumour DNA (ctDNA) are small fragments of DNA released by tumours 
into the circulation. These fragments contain pathogenic mutations which can be 
detected and quantified by various next generation sequencing approaches to monitor 
tumour burden. Many ctDNA analyses rely on sequencing of tumour tissue using large 
sequencing panels, querying hundreds of genes to find candidate ctDNA biomarkers for 
follow-up. Whilst this approach has been successfully implemented to track changes in 
tumour burden over time, it requires the sequencing of tumour tissue – which is 
difficult to obtain and may not accurately represent the entire genomic landscape of 
tumours. Hence, this study designed a targeted DNA sequencing panel to detect 
pathogenic mutations directly from the plasma of gastric and colorectal cancer patients. 
In addition, the criteria of selecting ctDNA biomarkers was investigated in colorectal 
cancers by comparing the ability of mutations in tumour suppressor genes and 
oncogenes to track changes in tumour burden throughout chemotherapy treatment.  
 
The gastrointestinal cancer sequencing panel (GI cancer panel) designed in this study 
successfully identified pathogenic mutations in the plasma of gastric and colorectal 
cancer patients. By restricting the panel to only 21 genes, and designing specialised 
oligonucleotide sequencing primers, a high analytical sensitivity was reached. 
Mutations were successfully identified down to a frequency of 0.5%. This study also 
identified technical challenges associated with ctDNA sequencing approaches –such as 
distinguishing pathogenic mutations from sequencing errors and benign variants found 
in the plasma. Finally, this study highlighted several factors that should be considered 
when selecting ctDNA biomarkers – including the necessity to monitor multiple 
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mutations to better represent the total tumour burden. Overall, this study has generated 
evidence supporting the implementation of ctDNA technologies into the healthcare 
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CHAPTER 1: INTRODUCTION 
1.1. Gastrointestinal Cancers 
Gastrointestinal (GI) cancers include any cancer arising in the gastrointestinal tract and 
accessory digestive organs. However, in this thesis I will use the term, “gastrointestinal 
cancers”, to refer exclusively to those of the stomach, colon, and rectum. Whilst 
cancers of the oesophagus, anus, and accessory organs are all important malignancies, 
they are not as common as gastric and colorectal cancers and as such, were not the topic 
of this research project (1).  
 
1.1.1 Epidemiology of Gastrointestinal Cancers 
GI cancers are significant contributors to the global cancer burden. With approximately 
2.8 million new diagnoses and 1.6 million deaths annually, these cancers are amongst 
the most frequently diagnosed and fatal worldwide. New Zealand has among the 
highest rates of GI cancers globally – especially colorectal cancers, for which New 
Zealand rates, alongside Australia, are ranked highest in the world (1). Colorectal 
cancer is the second most common cancer diagnosis in New Zealand males and 
females, and gastric cancer is the tenth most common cancer diagnosis in New Zealand 
males only (2). There are significant ethnic inequalities in the diagnosis and 
management of GI cancers in New Zealand. Māori and Pacific people harbour a 
disproportionately high burden of GI cancer-associated morbidity and mortality 





1.1.2 Classification of Gastrointestinal Cancers  
There are multiple ways in which GI cancers are classified. Anatomical classifications 
are based on the organ in which cancers originate. Gastric cancers originate anywhere 
in the gastric cardia, fundus, body, antrum, and pylorus (5). Proximal cancers of the 
stomach are classified according to their distance from the gastric cardia – the opening 
of the oesophagus into the stomach. Tumours with epicentres 1-5 cm above the gastric 
cardia are classified as distal oesophageal cancers. Those with epicentres 1 cm above or 
2 cm below the gastric cardia are true gastroesophageal junction cancers. Finally, 
tumours with epicentres 2-5 cm below the gastric cardia are subcardial gastric cancers 
(6). Colorectal cancers originate anywhere from the caecum through to the rectum (5). 
Histological classifications depend on the tissue of origin and include carcinomas, 
lymphomas, sarcomas, and carcinoid tumours. Carcinomas are the most common 
cancer of the GI tract and can be further subclassified based on their morphologies into 
subtypes such as adenocarcinomas, signet ring cell carcinomas, and squamous cell 
carcinomas (7).  
 
The Lauren classification is specific to gastric adenocarcinomas, and stratifies tumours 
into either diffuse, intestinal, or mixed subtypes depending on their morphology. 
Diffuse adenocarcinomas are poorly differentiated and often contain signet-ring cells. 
In contrast, intestinal adenocarcinomas are well to moderately differentiated cancers 
that form glandular structures. Mixed adenocarcinomas display a combination of both 




1.1.3 Risk Factors for Gastrointestinal Cancers  
There are a multitude of risk factors associated with the development of GI cancers. 
Many lifestyle factors such as smoking, alcohol, processed meats, and a high body 
mass index (BMI) are all risk factors for developing GI malignancies. In contrast, 
physical exercise and a high fruit and vegetable diet are protective factors (1).  
 
Infectious risk factors are more common in gastric cancers. Approximately 90% of non-
cardia gastric cancers have an underlying Helicobacter pylori (H. pylori) infection (9). 
H. pylori actively promotes gastric carcinogenesis through a multitude of virulence 
factors, such as the cytotoxin-associated gene A (CagA) protein, which stimulates 
cellular proliferation and reduces apoptosis (10, 11). Other infectious agents, such as 
the Epstein-Barr Virus (EBV), have been implicated in gastric carcinogenesis (12).  
 
A significant proportion of GI cancer risk is inherited. There are three main familial 
syndromes which can give rise to early GI cancers – hereditary diffuse gastric cancer 
(HDGC), familial adenomatous polyposis (FAP), and hereditary non-polyposis 
colorectal cancer (HNPCC). HDGC is a heritable cancer syndrome associated with the 
development of diffuse gastric cancer and lobular breast cancer (13). Most cases are 
caused by germline mutations in the E-cadherin (CDH1) gene, resulting in 33 to 70% of 
carriers developing diffuse gastric cancer by 80 years of age (14-16). FAP and HNPCC 
are two familial cancer syndromes associated with the early development of colorectal 
cancer. FAP is caused by rare germline mutations in APC or MUTYH genes – leading 
to the development of hundreds to thousands of colorectal polyps, which may become 
malignant over time (17). HNPCC is more common than FAP and is caused by 
germline mutations in DNA mismatch repair (MMR) genes (18). All three conditions 
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are managed by routine endoscopic surveillance and removal of affected organ/s at 
early signs of dysplastic epithelial changes (13, 17, 18).  
 
1.1.4 The Genetics of Gastrointestinal Cancers 
Like all cancers, GI cancers develop due to the acquisition of somatic mutations over 
time. This facilitates the progressive transformation of normal somatic cells into 
malignant clones capable of proliferating throughout the body. A process of clonal 
evolution ensues whereby subclones harbouring advantageous genotypes are expanded 
in the cancer cell population (19). This evolutionary process is dynamic and results in 
tumours that are genetically heterogeneous in space and over time – a phenomenon 
termed “intratumour heterogeneity”. Spatial intratumour heterogeneity arises when 
subclones are separated either by metastasis or physical barriers such as blood vessels 
and tissue planes. Temporal heterogeneity is a consequence of successive clonal 
expansions in response to changing selection pressures for example, over the course of 
a drug therapy (20).  
 
Since the development of next generation sequencing (NGS) technologies, the 
molecular events underpinning GI cancer development have become clearer. In 
addition to conventional anatomic and histological classifications, molecular 
classifications have been applied clinically to guide prognostication and inform 
therapeutic decisions. Due to their extensive heterogeneity, GI cancers have numerous 
molecular classifications. However, there are similarities in the genetic and epigenetic 




A prominent molecular pathway implicated in GI carcinogenesis is the WNT signalling 
pathway.  This pathway normally regulates stem cell development although aberrations 
have been in found numerous types of malignancies – including GI cancers (21). 
Alterations in WNT signalling genes, such as APC and CTNNB1, are common features 
of GI cancers (22). In addition, genes involved in TGF-β and SMAD signalling, two 
pathways implicated in the epithelial-mesenchymal transition (EMT), are found in GI 
cancers (22, 23).  
 
Microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), and 
chromosomal instability (CIN) are three pathways that drive the development of GI 
malignancies. MSI cancers arise due to defects in the DNA mismatch repair system, 
leading to frequent insertions, deletions, or single nucleotide errors in highly repetitive 
regions of the genome. Approximately 15% of gastric and colorectal cancers display 
microsatellite instability (24). CIMP cancers arise due to hypermethylation of CpG 
dinucleotides in various gene promoters – leading to epigenetic silencing of affected 
genes. Methylation phenotypes are unique to each cancer type and are associated with 
distinct mutation patterns (25). Finally, CIN cancers are characterised by large-scale 
chromosomal aberrations that arise due to defects in cellular physiology – such as 
chromosome cohesion and cell-cycle regulation (26).  
 
1.1.4.1 The Genetics of Gastric Cancers  
Gastric cancers can be stratified into one of four molecular subtypes - the Epstein-Barr 
virus-positive (EBV+), microsatellite instability (MSI), genomically stable (GS), and 




EBV+ tumours are characterised by a high EBV burden and extensive promoter 
methylation. EBV-associated CIMP features CDKN2A promoter methylation, which is 
distinct from the MHL1 promoter methylation typical of MSI cancers. EBV+ tumours 
are also enriched for PIK3CA mutations (12). Recurrent amplifications at loci 
harbouring immune signalling genes are common in EBV+ tumours – making these 
cancers good candidates for targeted therapy with immune checkpoint inhibitors (12, 
27). EBV+ tumours rarely contain TP53 mutations, which are common in other gastric 
cancers, but are enriched for ARID1A and BCOR mutations (12).  
 
MSI gastric cancers harbour a CIMP more consistent with colorectal cancers – 
displaying characteristic MLH1 promoter hypermethylation. In addition, MSI gastric 
cancers exhibit extensive hypermutation. The mutation profiles of these cancers tend to 
lack targetable amplifications and BRAF mutations found in other MSI cancers of the 
gastrointestinal tract, however mutations in PIK3CA, ERBB3, ERBB2, and EGFR may 
be present (12). Like the EBV+ subtype, MSI tumours are associated with immune 
signalling signatures and thus, are good candidates for targeted immunotherapies (27).   
 
The last two molecular subtypes are distinguished based on their extent of aneuploidy. 
CIN tumours possess substantial chromosomal aberrations whilst GS tumours do not. 
GS gastric cancers are enriched for the diffuse histological subtype and harbour 
frequent CDH1 and RHOA mutations (12). In contrast, CIN tumours are commonly of 
the intestinal histological subtype and contain frequent TP53 mutations and 
amplifications of genes encoding receptor tyrosine kinases (RTKs) such as EGFR, 
ERBB2, and ERBB3 (12). Therefore, CIN cancers are good candidates for therapies that 
target RTKs (28).  
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1.1.4.2 The Genetics of Colorectal Cancers  
The genomic instability driving colorectal carcinogenesis arises from one of several 
mechanisms. CIN is the most common mechanism although genomic instability may 
also arise due to MMR defects or the CIMP (29).  
 
The CIN pathway is commonly initiated by mutations in the APC tumour suppressor 
gene, encoding a negative regulator of β-catenin (17, 29). In APC wild-type colorectal 
cancers, mutations in the β-catenin gene itself, CTNNB1, initiate aberrant WNT 
signalling (29). Following these initiating events, subsequent mutations drive the 
malignant transformation of normal epithelial cells to adenomas and eventually 
carcinomas. KRAS mutations occur early in this transformation – promoting cell 
survival and suppression of apoptosis. Mutations and deletions affecting TP53, and 
genes involved in the TGF-β signalling pathway, such as SMAD2 and SMAD4, proceed 
– marking the transition from adenoma to invasive carcinoma. Oncogenic mutations of 
BRAF and PIK3CA are also implicated in the CIN pathway (30).  
 
Colorectal cancers may also develop due to MSI on account of inherited or somatic 
mutations in MMR genes or by aberrant methylation of the MLH1 promoter (18, 31). 
Epigenetic silencing of MLH1 commonly co-occurs with BRAF mutations in sporadic 
colorectal cancers (32).  
 
Finally, the CIMP is a prominent molecular pathway driving colorectal carcinogenesis. 
CIMP tumours are stratified into CIMP-high and CIMP-low based on the number of 
methylated markers. CIMP-high tumours are associated with BRAF mutations whereas 
CIMP-low tumours are associated with KRAS mutations (30).  
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1.1.5 Diagnosis and Management of Gastrointestinal Cancers  
Diagnosis of gastric and colorectal cancers is made through endoscopic assessment of 
the affected organ and confirmed by histopathologic assessment of a biopsy. 
Subsequent computed tomography (CT) assessment of the thorax, abdomen, and pelvis 
allows accurate staging. More specialised imaging techniques, such as magnetic 
resonance imaging (MRI) and positron emission tomography (PET) scans, may be used 
to assess equivocal lesions. The three treatment modalities used in GI cancers are 
surgery, radiotherapy, and drug therapies – including chemotherapy, immunotherapy, 
and targeted agents. Depending on the cancer stage, all three of these modalities may be 
used in combination. Neoadjuvant (pre-surgical) and/or adjuvant (post-surgical) 
chemotherapy or chemoradiotherapy is indicated in most patients with resectable 
cancers. Depending on stage, cancers may be treated with curative intent, however 
treatment goals shift to life-extension or palliation as the disease progresses (33-36)  
 
Despite surgical, radiotherapeutic, and drug interventions, relapse rates of gastric and 
colorectal cancers are between 40 and 60% (37-41). The liver is the most common site 
of metastasis for both gastric and colorectal cancers. The peritoneum and lung, among 
other sites, may also be affected (7). Whilst post-operative surveillance programmes 
may be implemented to detect early recurrence, often these programmes have no impact 
on overall- or relapse-free survival rates in both gastric and colorectal cancers (42, 43). 
Current surveillance techniques include endoscopic investigations, routine imaging of 
sites prone to metastasis, and serum protein biomarker assays (42, 43).  
 
Several serum protein biomarkers have been utilised for gastric and colorectal cancer 
surveillance – namely carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 
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(CA19-9). These protein biomarkers correlate well with clinicopathological features, 
such as the degree of differentiation and TNM stage. They can also be used to detect 
early signs of cancer recurrence (44-46). However, the ability of protein biomarkers to 
detect recurrence is variable, with sensitivities ranging from 15 to 70% in gastric and 
colorectal cancers (45, 46). Factors such as disease stage and metastatic dissemination 
influence the concentrations of protein biomarkers, with higher concentrations found in 
late-stage cancers and those with liver metastases (45, 46).  
 
Due to the unspecific nature of serum protein biomarkers, and the risks of radiation 
exposure associated with many imaging modalities, there is a need for novel 
biomarkers to aid in the diagnosis and management of gastrointestinal cancers.  
 
1.2 Circulating Tumour DNA 
Circulating nucleic acids were first reported by Mandel and Métais in 1948 (47). Cell-
free DNA (cfDNA) is normally found in low concentrations in the blood however, 
concentrations are raised in several human diseases – including cancer (48). The origins 
of cfDNA differ between health and disease. In healthy individuals, cfDNA originates 
predominantly from haemopoietic cells, with smaller contributions from vascular 
endothelial cells and hepatocytes. In contrast, cfDNA in cancer patients tends to 
originate directly from malignant tissue itself (49). Since the discovery of tumour-
specific alterations in cfDNA, the phrase “circulating tumour DNA” (ctDNA) has been 
coined to describe the fraction of cfDNA that is of tumour origins (50). The exact 
mechanisms by which ctDNA is released into the blood are contested, however three 
main mechanisms have been postulated – apoptosis, necrosis, and secretion by tumour 




1.2.1 Physical Properties of Circulating Tumour DNA  
The half-life of ctDNA ranges from 16 minutes to 2.5 hours, depending on factors such 
as temperature, and serum proteins and lipids (51, 52). ctDNA is degraded by 
circulating nucleases and excreted by the kidneys (52, 53). The size distribution of 
ctDNA fragments cluster at approximately 170 bp, corresponding to the length of DNA 
wrapped around a single nucleosome, although fragment lengths are variable (54, 55).  
 
1.2.2 Tumour vs. Liquid Biopsies in Cancer 
Many cancer diagnostic and surveillance methods require sampling of tumour tissue. 
Conventional sampling methods, such as endoscopic and surgical biopsies, are invasive 
procedures subject to a plethora of complications which can lead to poor sample quality 
(51). ctDNA analyses have been proposed as an alternative to tumour biopsies. These 
so-called ‘liquid biopsies’ have clear advantages over tissue biopsies due to their 
minimally invasive nature and reduced reliability on specialist operators to acquire 
samples. In practice, this means ctDNA can be sampled at serial timepoints over a 
disease course. In addition, liquid biopsies reduce the impacts of tumour sampling bias 
(51).  
 
Tumour sampling bias arises due to the spatial and temporal genetic heterogeneity of 
cancers. Therefore, single tumour biopsies are unlikely to capture the entire genomic 
landscape of a cancer at a single point in time. Furthermore, multiple tumour biopsies 
are rarely taken and as such, their ability to track genomic changes over time is limited. 
Liquid biopsies are positioned to capture a wider breadth of tumour heterogeneity as 
they can survey DNA from multiple sites and timepoints (51). In instances where 
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tumour biopsies of primary and metastatic tumours lack concordance, liquid biopsies 
have successfully identified mutations found at both sites (56). ctDNA analyses have 
also successfully identified resistance mutations that were absent from the primary 
tumour (57, 58). As such, the applications of liquid biopsies far outweigh those of the 
tumour biopsies currently used in clinical practice.   
 
1.2.3 Analysis of Circulating Tumour DNA 
Many different methods for the identification and quantification of ctDNA have been 
established – from allele-specific PCR (59) and multiplexed digital PCR assays (60, 61) 
able to identify hotspot mutations at single loci, to larger-scale targeted (62-64) and 
whole genome sequencing (WGS) approaches (65, 66) able to capture a wide breadth 
of genomic alterations. Epigenetic approaches, such as methylation profiling and DNA 
fragment length analyses are also being developed as alternatives to genomic analyses 




The application of ctDNA has been investigated at many stages of cancer management 
– from obtaining an early diagnosis through to tracking treatment response in advanced 
disease (51) (Figure 2). Strong correlations with clinicopathological features, such as 
tumour size, stage, and the presence of metastatic disease, allow clinicians to use 
ctDNA as a prognostic biomarker (54, 58). In addition, ctDNA can be used as 
predictive biomarkers to stratify patients based on their likelihood of responding to 
treatments such as surgery and drug therapies (67-69). 
 
Figure 1. Analysis of Circulating Tumour DNA. Methods of ctDNA analysis include 
screening for specific mutations and small insertions/deletions (indels) at single loci, to targeted 
and whole genome sequencing approaches capable of surveying a larger breadth of the genome. 
Types of alterations detectable in ctDNA include genetic alterations such as mutations and 
structural chromosomal changes, and epigenetic alterations such as methylation profiles and 
DNA fragment length patterns. Created with BioRender.com 
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Serial monitoring of ctDNA concentrations can be used to track changes in tumour 
burden throughout a course of treatment. These liquid biopsies often outperform 
conventional imaging modalities (62, 68, 70, 71) and serum protein biomarker assays 
(62, 68, 70) in their ability to detect disease progression events. However, due to 
biological factors influencing ctDNA release into the circulation, concentrations do not 
always accurately reflect the total tumour burden. For example, primary brain tumours 
release minimal quantities of ctDNA into the bloodstream due to disruption from the 
blood-brain barrier (58). Furthermore, peritoneal metastases shed less ctDNA into the 
circulation due to the low vascularity of the peritoneum compared to other metastatic 
sites, such as the liver (67). These biological factors must be considered when 
quantifying ctDNA to monitor disease burden.   
 
Figure 2. Applications of Circulating Tumour DNA. ctDNA can be used to detect and 
monitor cancers throughout their disease course. Ultrasensitive methods of analysing ctDNA 
can be implemented to screen for and detect cancers earlier than other diagnostic methods. 
Following diagnosis, ctDNA can be used to aid in prognostication and to predict response to 
various treatments – such as surgery and adjuvant chemotherapy. Following treatment, ctDNA 
analyses can be used to examine changes in the tumour burden to detect disease progression 




1.2.4 Identification of ctDNA Biomarkers  
Quantification of ctDNA is commonly done by measuring the frequency of pathogenic 
mutations in plasma. Identification of these ctDNA biomarkers is made challenging by 
the presence of other circulating mutations found in normal genomic DNA (gDNA). 
These benign variants may arise from the germline or be associated with clonal 
haematopoiesis of indeterminate potential (CHIP) (72, 73). CHIP is an aging-related 
phenomenon in which haematopoietic stem cells produce white blood cells harbouring 
somatic mutations associated with myeloid malignancies. These mutations are benign 
but are commonly misclassified as pathogenic by ctDNA analyses due to their 
association with carcinogenesis (74). Circulating germline and CHIP-associated 
mutations are poor ctDNA biomarkers as their frequencies are not influenced by 
changes in the tumour burden. These benign mutations can be identified and excluded 
by sequencing matched white blood cells alongside ctDNA samples – leaving only 
pathogenic mutations for further analysis (75).  
 
Once pathogenic mutations are distinguished from benign variants, careful 
consideration must be taken to select the appropriate type and number of ctDNA 
biomarkers for follow-up. Mutations that occur earlier in a tumour’s evolution are 
generally better markers of the total tumour burden as they are found in a larger 
proportion of the cancer cell population (76). However, mutations may be lost from the 
cancer genome due to clonal evolution – making single locus assays prone to 
misrepresenting the tumour burden. Therefore, monitoring multiple mutations increases 
the chances of ctDNA detection as each variant provides an independent opportunity of 
detecting a mutant molecule in a sample of DNA fragments (51).  
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1.3 Circulating Tumour DNA in Gastrointestinal Cancers 
1.3.1 ctDNA in Gastric Cancer 
A variety of methods have been applied to detect and monitor ctDNA in gastric cancers 
– from ddPCR assays tracking mutations identified by tissue sequencing, to direct 
targeted- and whole-genome sequencing of plasma (77-84). In studies where tissue and 
plasma sequencing were both performed, concordance was variable between mutations 
identified in the two sample types (77-79). ctDNA has been shown to capture a wider 
breadth of tumour heterogeneity than gastric tissue samples – indicating direct plasma 
sequencing may be a suitable alternative to tissue sequencing in gastric cancers (79). 
Serial monitoring of ctDNA has successfully identified disease progression events 
earlier than CT scans and serum protein biomarkers in gastric cancers (75, 81, 82, 85-
87). Furthermore, ctDNA analyses have been used to identify early resistance to 
systemic therapies (82, 87-89). However, selecting the appropriate type and number of 
ctDNA biomarkers for gastric cancer surveillance has also proved challenging (76). 
 
ctDNA concentrations correlate well with clinicopathological features of gastric cancer. 
Higher ctDNA levels are positively associated with cancer size, stage, and the extent of 
local or distant spread (77, 80-82, 90). ctDNA concentrations also correlate with 
histological subtypes – with ctDNA being more frequently detected in intestinal-type 
gastric cancers (75). Metastatic dissemination is generally associated with higher 
ctDNA concentrations, except in metastasis to the peritoneum (76, 81). This 
observation highlights that ctDNA concentrations may not always represent the degree 




1.3.2 ctDNA in Colorectal Cancer 
Targeted- and whole-genome sequencing approaches have also been implemented to 
detect and monitor ctDNA in colorectal cancers. Similar to gastric cancers, most 
published studies have utilised tissue sequencing to identify pathogenic mutations (62, 
68, 91, 92) although direct plasma sequencing has also proven successful (93). Variable 
concordance between tissue and plasma mutations is found in colorectal cancers 
although again, plasma sequencing has shown to capture a wider breadth of tumour 
heterogeneity  (60, 94). Monitoring tumour burden by ctDNA has identified disease 
progression events earlier than imaging studies and serum protein biomarkers (62, 68, 
91, 93, 95). However, one published study reported the highest prognostic value was 
reached when ctDNA and serum protein biomarkers were combined (96). Challenges in 
selecting the appropriate type and number of ctDNA biomarkers have also been 
reported in colorectal cancers (91). 
 
Like gastric cancer, ctDNA concentrations correlate well with various 
clinicopathological features of colorectal cancer. ctDNA concentrations increase with 
tumour stage and are higher in patients with liver metastases (68). Again, ctDNA is less 




1.4 Study Aims and Significance  
This study aims to investigate the application of ctDNA to the management of 
gastrointestinal cancers. Specifically, this study intends to improve the detection of 
ctDNA through the design of a targeted DNA sequencing panel, and to further explore 
the criteria for ctDNA marker selection. The major aims are outlined as follows:  
 
1. Design a targeted DNA sequencing panel for gastric and colorectal cancers.  
2. Test the performance of a targeted DNA sequencing panel on gastric and 
colorectal plasma samples.  
3. Investigate whether tumour suppressor mutations detected in the ctDNA are 
better markers of colorectal tumour burden than mutations in oncogenes.  
 
This project builds on the results of a recent colorectal ctDNA study conducted in the 
Cancer Genetics Laboratory, which used ctDNA analyses to monitor the tumour burden 
of 60 colorectal cancer patients throughout treatment with chemotherapy (62). This 
study used a commercially available colorectal sequencing panel of 71 genes to identify 
pathogenic mutations in tumour tissue, which were subsequently tracked in the plasma. 
In contrast, this project aims to design a targeted sequencing panel, with a smaller 
number of gene targets, to maximise the sensitivity of detecting mutations directly from 
the plasma of patients with gastric and colorectal cancers.  
 
Completion of the above aims will result in the establishment of a versatile plasma 
sequencing strategy for gastrointestinal cancers. It may also highlight technical 
considerations that should be taken when designing ctDNA assays, such as the type and 
number of mutations that should be tracked with digital PCR. Overall, this study aims 
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to generate evidence supporting the implementation of ctDNA technologies into the 







2. CHAPTER 2: METHODOLOGY 
2.1 Custom Design of a Targeted DNA Sequencing Panel 
A combination of methods were implemented to design a targeted DNA sequencing 
panel for gastrointestinal cancers (the “GI cancer panel”). Firstly, a list of gastric cancer 
genes was manually curated by analysing COSMIC datasets and 20 published gastric 
cancer sequencing studies. Secondly, a list of colorectal cancer genes was identified 
from existing sequencing data of 60 colorectal cancer patients (62).  Finally, gastric and 
colorectal cancer gene lists were combined to produce the final list of gene targets for 
the GI cancer panel.  
 
2.1.1 The Pathogenic Catalogue Of Somatic Mutations In Cancer 
(COSMIC) Dataset  
The Catalogue Of Somatic Mutations In Cancer (COSMIC) database was used to 
access manually curated somatic mutation data from cancer samples (98). The targeted 
screens data (version 91) was filtered to exclude non-gastric samples, downloaded from 
cancer.sanger.ac.uk/cosmic/download, and read into the R computational environment. 
The dataset contained thousands of data points – each representing a single mutation 
identified by targeted sequencing of a single tumour sample.  
 
2.1.1.1 Functional Analysis Through Hidden Markov Models (FATHMM) 
To select cancer driver genes, the FATHMM pathogenicity filter was used to filter out 
variants not predicted to cause cancer. Briefly, FATHMM works by utilising Hidden 
Markov Models (HMM) to predict the functional consequences of mutations that map 
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within the model. A training dataset containing cancer-associated and putatively neutral 
variants was used to create pathogenicity weights for different protein domains. The 
functional impact of mutations was then estimated based on where the corresponding 
amino acid change occurred in the protein domain. This prediction model classified 
mutations as pathogenic if their functional impacts were deemed to promote cancer 
development. Mutations were classified as neutral if their impact was benign, or 
unknown if their effect on protein function was equivocal (99, 100).  
 
Once non-pathogenic mutations were excluded, mutation frequencies were calculated 
by dividing the number of samples containing a mutation in each gene by the total 
number of samples in the dataset (n = 1,840). The R script for this analysis is displayed 
in Appendix 1.  
 
2.1.2 The Cancer Gene Census  
Genes identified in the pathogenic dataset were next cross-referenced to the cancer 
gene census. Each gene was manually searched in the census 
(cancer.sanger.ac.uk/census) to obtain their tier classification. Genes not found in tier 
one of the Cancer Gene Census were excluded.  
 
2.1.3 The Unfiltered COSMIC Dataset    
A secondary list of gastric cancer genes was generated from a COSMIC dataset 
containing mutations of all FATHMM classifications. Samples in this unfiltered dataset 
were sequenced by both targeted and whole-genome approaches. This dataset was 




a&sh=all&in=t&src=tissue&all_data=n. Only gastric carcinoma samples were 
included. Mutation frequencies were calculated by dividing the number of samples with 
mutations in each gene by the number of samples tested for each gene.  
 
2.1.4 Search Criteria for Published Gastric Cancer Sequencing Studies  
The preliminary gastric gene list was cross-referenced against mutations found in 20 
published gastric and gastroesophageal cancer sequencing studies. Studies were 
identified by searching PubMed and Google Scholar databases. To reduce study 
numbers, only those published from 2010 onwards were considered. Search terms such 
as “cancer”, “diffuse”, “gastric”, “gastroesophageal”, “genomic”, “intestinal”, 
“molecular”, “mutation”, and “sequencing” were used to identify studies for further 
assessment. Only mutations and small insertions and deletions were considered in this 
cross-reference analysis; copy number alterations were excluded due to their inability to 
be detected by targeted sequencing panels.  
 
Studies not sequenced with NGS technologies were excluded from further analysis. A 
combination of WGS and targeted NGS approaches were represented in the 20 included 
studies. Of the 20 studies, six were included due to their sequencing of 
gastroesophageal junction tumours. In addition, an oesophageal adenocarcinoma 
sequencing study was included. One study that sequenced peritoneal carcinomatosis 
samples and two studies that implemented direct plasma sequencing were also 
included. Finally, study cohorts from a range of different ethnicities, including Asian 
and Caucasian populations, were included to ensure ethnic differences in mutation 
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patterns were considered. A full list of studies used for the cross-reference analysis are 
outlined in Appendix 2.  
 
2.1.5 Assessment of Initial Primer Design  
Following the design of the GI cancer panel’s oligonucleotide primers, .BED files 
representing coverage of target regions were generated. .BED files were reviewed in 
the NCBI Genome Browser 
(ncbi.nlm.nih.gov/genome/gdv/browser/genome/?id=GCF_000001405.25) to identify 
target regions with poor coverage. The Genome Reference Consortium Human Build 
37 (GRCh37) was used as the reference genome.  
 
2.2 Patient Samples  
2.2.1 Ethical Approval  
Ethical approval for independent gastric and colorectal ctDNA studies was obtained by 
the Ministry of Health’s, Health and Disability Ethics Committee (reference numbers 
18/NTA/190 and 16/STH/158, respectively).  
 
2.2.2 Gastric Cancer Patients 
Patients were recruited from the Seoul National University Hospital in Seoul, South 
Korea. Eligible patients were those with histologically confirmed gastric 
adenocarcinomas scheduled to receive standard of care treatment. Patients with 
concomitant advanced non-gastric malignancies, a haemoglobin of >100 g/L, or a 
clinically significant bleeding disorder that rendered venepuncture unsafe, were 
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excluded from the study. Patients were willing to comply with routine follow-up and 
their written informed consent was obtained prior to entry into the study.   
 
2.2.3 Colorectal Cancer Patients 
Patients being treated in the Southern District Health Board of New Zealand were 
recruited by their lead clinician. Eligible patients were those with colorectal cancer 
scheduled to receive standard of care treatment. Patients with concomitant advanced 
non-colorectal malignancies, a haemoglobin of >100 g/L, or any significant bleeding 
disorder that would render venepuncture unsafe were excluded from the study. Patients 
were willing to comply with routine follow-up and their written informed consent was 
obtained before entry into the study.  
 
2.2.4 Sample Collection  
Consented patients with confirmed eligibility from both the gastric and colorectal 
studies had whole blood samples collected by venepuncture or a central venous access 
device. Gastric cancer patients had two 8 mL blood samples collected before and after 
treatment – either surgery or chemotherapy. Samples were collected into tubes 
containing the anticoagulant, ethylenediaminetetraacetic acid (EDTA), and plasma was 
separated within four hours of collection. Colorectal cancer patients had up to two 10 
mL blood samples collected prior to each cycle of chemotherapy or at routine follow-
up. Samples were collected into Roche Cell-Free DNA Collection Tubes (Roche, 
Switzerland) and plasma was separated within seven days of collection. In addition, 
colorectal patients had tumour blocks taken from their resected primary or metastatic 
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tumours, which were subsequently fixed with formalin and embedded in paraffin 
(FFPE) until further processing.  
 
Whole blood samples were centrifuged at 200 rcf for ten minutes, then immediately 
recentrifuged at 1,600 rcf for a further ten minutes. Plasma was carefully removed and 
centrifuged again at 1,600 rcf to pellet any residual material. The plasma supernatant 
was transferred to clean collection tubes and stored at -80°C until transport to the 
Cancer Genetics Laboratory (Department of Biochemistry, University of Otago, 
Dunedin, New Zealand).  
 
Plasma was separated from gastric blood samples in the Seoul National University 
Hospital laboratories and transported to the Cancer Genetics Laboratory on dry ice. 
Upon arrival, plasma samples were refrozen at -80°C until DNA extraction. Colorectal 
blood samples were immediately transported to the Cancer Genetics Laboratory for 
plasma separation and storage at -80°C until DNA extraction could be performed.  
 
2.3 Sample Preparation and Storage  
DNA had been previously extracted from colorectal FFPE samples and stored at -80°C. 
However, ctDNA from gastric and colorectal plasma samples was extracted, quantified, 




2.3.1 ctDNA Extraction, Quantification, and Storage 
ctDNA was extracted from plasma samples using the QIAamp Circulating Nucleic 
Acid Kit (Qiagen, Germany) as per the manufacturer’s instructions for 5 mL of plasma. 
UltraPure DNAse/RNAse Free Distilled Water (Thermo Fisher Scientific, USA) was 
used to elute DNA from the spin column instead of the recommended Buffer AVE. 
Extracted ctDNA samples were quantified using the Qubit 2.0 Fluorometer with the 
dsDNA High Sensitivity Kit (Thermo Fisher Scientific, USA) as per the manufacturer’s 
instructions. The size of extracted DNA fragments was measured using the Agilent 
2100 Bioanalyzer (Agilent Technologies, USA). Extracted DNA samples were stored 
in low-bind tubes (Eppendorf, Germany) at -80°C until further use.   
 
2.4 Next Generation Sequencing  
Targeted sequencing of colorectal FFPE samples, using the QIAseq Targeted DNA 
Human Colorectal Cancer Panel (Qiagen, Germany), had been done in a previous 
ctDNA colorectal study (62). Initial testing of the GI cancer panel was performed by 
sequencing FFPE and ctDNA samples from two colorectal cancer patients (M043 and 
M047). Data generated from these two patients was used to design an additional 100-
oligonucleotide primer booster panel. This booster panel was pooled with the base GI 
cancer panel and used to sequence ten gastric cancer ctDNA samples. Targeted 
sequencing of gastric and colorectal samples using the GI cancer panel was performed 




2.4.1 Library Preparation  
DNA sequencing libraries were prepared using the QIAseq Targeted DNA Panel Kit 
(Qiagen, Germany). Colorectal FFPE DNA and ctDNA samples were diluted to achieve 
a target of 75 ng of FFPE DNA and 20 ng of ctDNA in 15 μL – although ctDNA inputs 
were variable due to plasma DNA yields. Gastric ctDNA samples were diluted to 
achieve a target of 40 ng of ctDNA in 15 μL – although ctDNA inputs were variable 
due to plasma DNA yields. A Human Genomic DNA (Roche, Switzerland) control 
library was prepared using 28.8 ng of gDNA for sequencing alongside gastric ctDNA 
samples.  Diluted samples were concentrated using the Savant SpeedVac High Capacity 
Concentrator (Thermo Fisher Scientific, USA) to achieve the desired quantity of DNA 
in 15 μL.  
 
Library preparations were performed according to the manufacturer’s instructions. 
Before the fragmentation step, 1.25 μL of FG solution (Qiagen, Germany) was added to 
ctDNA samples to inhibit enzymatic fragmentation. For the target enrichment step, 
thermal cycling conditions optimised for the base panel of 2,752 primers, and pooled 
base and booster panels of 2,852 primers, were used (Table 1).   
 
Table 1. Thermal cycling conditions for target enrichment. Conditions below were used for 
both the base (2,752 primers) and pooled base and booster (2,852 primers) GI cancer panels.  
Step Time Temperature 
Initial Denaturation 
13 minutes 95°C 
2 minutes 98°C 
6 Cycles 
15 seconds 98°C 
15 minutes 65°C 
1 Cycle 5 minutes 72°C 




For the universal PCR step, thermal cycling conditions optimised for the GI cancer 
panel were used (Table 2). 23 cycles of 98°C for 15 seconds and 60°C for 2 minutes 
were used for both FFPE and ctDNA samples, instead of the recommended 25 cycles 
for FFPE samples and 23 cycles for ctDNA samples.  
 
Table 2. Thermal cycling conditions for universal PCR. Conditions below were used for 
both the base (2,752 primers) and pooled base and booster (2,852 primers) GI cancer panels.  
Step Time Temperature 
Initial Denaturation 
13 minutes 95°C 
2 minutes 98°C 
23 Cycles 
15 seconds 98°C 
2 minutes 60°C 
1 Cycle 5 minutes 72°C 
Hold 5 minutes - Infinite 4°C 
 
Following completion of library preparations, libraries were stored at -20°C until 
sequencing.  
 
2.4.2 Illumina Miseq Sequencing  
Prior to sequencing, libraries were combined and diluted to a concentration of 4 nM of 
DNA. This was done by quantifying the libraries using the Qubit 2.0 Fluorometer 
(Thermo Fisher Scientific, USA) and using the average fragment length, as determined 
by the Agilent 2100 Bioanalyzer (Agilent Technologies, USA), to calculate the 
molarity of each library. Only DNA fragments that were within the expected size 
distribution of Illumina sequencing libraries were used for this calculation. Secondary 
and tertiary peaks, comprised of double-stranded secondary structures (Figure 15), were 
ignored due to their denaturation into single-strands before sequencing. 4 nM libraries 
were denatured by adding 5 μL of the library mix to 5 μL of fresh 0.2 M sodium 
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hydroxide. 990 μL of prechilled Hybridization Buffer (Illumina, USA) was added to the 
denatured libraries – resulting in a stock concentration of 20 pM. The denatured 20 pM 
library mix was then diluted to 8 pM, loaded into a MiSeq v2 reagent cartridge 
(Illumina, USA), and run on the MiSeq sequencing platform (Illumina, USA) for 300 
cycles of sequencing with 151 bp paired end reads.  
 
2.4.3 Data Analysis  
For all sequencing runs, output .fastq files were generated and downloaded from the 
Illumina Basespace Sequence Hub (Illumina, USA). Colorectal cancer sequencing data 
was analysed by both the GeneGlobe Data Analysis Centre (Qiagen, Germany) and a 
custom variant calling pipeline produced in the CLC Genomics Workbench (Qiagen, 
Germany). Gastric cancer sequencing data was analysed solely by the CLC Genomics 
Workbench pipeline. For analyses using the GeneGlobe Data Analysis Centre, .fastq 
files were uploaded to ngsdataanalysis2.qiagen.com/QIAseqDNA and a confidential 
panel catalogue identifier was used to complete analyses. Upon completion, output files 
containing mutation data sorted for each patient were downloaded and opened using 
Microsoft Excel. For analyses using the CLC Genomics Workbench, .fastq files were 
uploaded into the workbench and passed through a customised variant calling pipeline. 
Variants were called down frequencies of either 1% or 0.5%. The final list of annotated 
variants found in each sample was downloaded from the workbench and opened using 
Microsoft Excel.  
 
Pathogenic mutations were manually distinguished from benign variants according to 
the process detailed in chapter 4.1.3. Briefly, mutations with frequencies between 0.45-
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0.55 and 0.8-1.00 were excluded. Remaining mutations were searched using the 
COSMIC (cancer.sanger.ac.uk/cosmic), Varsome (varsome.com), and gnomAD 
(gnomad.broadinstitute.org) databases, using coding human genome variation society 
(HGVS.c) identifiers. 
  
2.5 Droplet Digital PCR Assays for Colorectal Cancer  
2.5.1 Design of Primers and Probes 
The primers and probes used to track pathogenic mutations in colorectal plasma 









Table 3. ddPCR primers and probes for pathogenic mutations identified in colorectal 
cancer patients. Letters in bold represent the differing nucleotides between mutant and wild-
type probes.   
Mutations Primer/Probe Sequence 
APC c.1495C>T 
Forward Primer GCTTACTAATGACCACTACAG 
Reverse Primer TCTCCAAAAGTCAAGTTTGT 
Mutant Probe ACACTAAGATGATATGCTGGAAT 
Wild-Type Probe CACTAAGACGATATGCTGGAA 
APC c.4271delC 
Forward Primer GGAATGGTAAGTGGCATTAT 
Reverse Primer GAGGTGTTTTACTTCTGCTT 
Mutant Probe CAGTGATCTTCAGATAGCCCT 
Wild-Type Probe AGTGATCTTCCAGATAGCCC 
APC c.4308delT 
Forward Primer  ATTATAAGCCCCAGTGATCT 
Reverse Primer TTGGTTTGAGCTGTTTGAG 
Mutant Probe CAAGCAGAAGAAAACACCTC 
Wild-Type Probe CAAGCAGAAGTAAAACACCTC 
BRAF c.1799T>A 
Forward Primer TCATGAAGACCTCACAGTAA 
Reverse Primer CTGTTCAAACTGATGGGAC 
Mutant Probe TGGTCTAGCTACAGAGAAATCTC 
Wild-Type Probe TGGTCTAGCTACAGTGAAATCTC 
KRAS c.35G>T 
Forward Primer AAGGCCTGCTGAAAATGACT 
Reverse Primer TAGCTGTATCGTCAAGGCAC 
Mutant Probe TAGTTGGAGCTGTTGGCGTAGG 
Wild-Type Probe TAGTTGGAGCTGGTGGCGTAG 
KRAS c.436G>A 
Forward Primer CTTAGCAAGAAGTTATGGAAT 
Reverse Primer TGATTTTGCAGAAAACAGAT 
Mutant Probe CATCAACAAAGACAAGACAGG 
Wild-Type Probe CATCAGCAAAGACAAGACAG 
PIK3CA c.1624G>A 
Forward Primer TGACAAAGAACAGCTCAAAGC 
Reverse Primer AGCACTTACCTGTGACTCCA 
Mutant Probe CCTCTCTCTGAAATCACTAAGCAGG 
Wild-Type Probe TCTCTGAAATCACTGAGCAGGAGA 
TP53 c.514G>T 
Forward Primer CATCTACAAGCAGTCACAG 
Reverse Primer TCACCATCGCTATCTGAG 
Mutant Probe CACATGACGGAGTTTGTGA 
Wild-Type Probe   ACATGACGGAGGTTGTGA 
TP53 c.586C>T 
Forward Primer 
Commerical TP53 Assay: BioRad, 






Forward Primer AGTTGCAAACCAGACCTC 
Reverse Primer TGTGGAGTATTTGGATGACA 
Mutant Probe CACCACACTATGTCAAAAAGTG 





2.5.2 Gradient ddPCR  
To determine the optimal melting temperature of primers and probes, gradient ddPCR 
assays were performed between 52°C and 62°C. Human Genomic DNA (Roche, 
Switzerland) was diluted down to 1 ng/μL and used as a positive control for wild-type 
probes. FFPE DNA was diluted down to 1 ng/ μL and used as a positive control for 
mutant probes. Control samples were pipetted into 96-well plates. Volumes of primers, 
probes, Supermix for Probes (No dUTPs) (Bio Rad, USA), and UltraPure 
DNAse/RNAse Free Water (Thermo Fisher Scientific, USA) were added according to 
Table 4. 96-well plates were then temporarily sealed and centrifuged using the Select 
Spin Plate Centrifuge (Select Bioproducts, USA).  
 
Table 4. Volumes of reagents used in ddPCR assays.  
Reagent Volume 
Supermix for Probe (No dUTPs) 11μL 
Forward Primer 0.66 μL 
Reverse Primer 0.66 μL 
Mutant Probe 0.22 μL 
Wild Type Probe 0.22 μL 
Water 3.24 μL 
Sample 6 μL 
Total 22 μL 
 
96-well plates were then uncovered and placed in the QX200 AutoDG Droplet Digital 
PCR System (Bio Rad, USA) to generate droplets as per the manufacturer’s 
instructions. Next, 96-well plates were sealed using the PCR Thermal Seal RT2KK 
(Excel Scientific Ltd, USA) and subjected to graded thermal cycling using the C1000 
Touch Thermal Cycler (Bio Rad, USA) to amplify DNA as per the conditions outlined 




Table 5. Thermal cycling conditions for ddPCR assays.  
Step Temperature Time 
Enzyme Activation 95.0°C 10 minutes 
Denaturation 94.0°C 30 seconds 
Annealing/Extension 52.0°C - 62.0°C 1 minute 
Enzyme Deactivation 98.0°C 
10 minutes 
(return to denaturation 39x) 
Hold 12.0°C Infinite 
 











Upon completion of thermal cycling, mutant and wild-type droplets were quantified 
using the QX200 Droplet Reader (Bio Rad, USA). The Rare Event Detection (RED) 
protocol was used to measure the fluorescence of mutant and wild-type probes. A 
threshold distinguishing positive from negative droplets was manually set for both 
mutant and wild-type assays using the QuantaSoft Analysis Pro Software (Bio Rad, 
USA). The temperature which best distinguished positive from negative droplets was 
chosen as the optimal melting temperature and was used in future assays.  
 
2.5.3 ddPCR Assays for Quantifying ctDNA in Colorectal Cancer 
Samples  
ddPCR assays used to quantify ctDNA in colorectal plasma samples were performed as 
outlined in chapter 2.5.2. UltraPure DNAse/RNAse Free Water (Thermo Fisher 
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Scientific, USA) was used as a negative control for mutant and wild-type probes. 
Patient FFPE samples and Human Genomic DNA (Roche, Switzerland) were used as 
positive controls for the mutant and wild-type probes, respectively. Thermal cycling 
was performed as per the conditions outlined in Table 5, using the optimised melting 
temperature determined by gradient ddPCR assays. Upon amplification, positive and 
negative droplets were quantified as outlined previously.  
 
The data generated by the QuantaSoft Analysis Pro Software (Bio Rad, USA) was 
downloaded and opened in Microsoft Excel. The number of mutant copies per mL 
plasma ± SE was calculated for each plasma collection cycle as follows.  
 
𝑀𝑢𝑡𝑎𝑛𝑡 𝐶𝑜𝑝𝑖𝑒𝑠 𝑃𝑒𝑟 𝑚𝐿 𝑃𝑙𝑎𝑠𝑚𝑎 =







Mutation concentrations were plotted to visualise fluctuations over the course of 
treatment.   
 
2.6 Research Contributions  
The colorectal sequencing data used to design the GI cancer panel and ddPCR assays 
was generated in a ctDNA study conducted in the Cancer Genetics Laboratory (62). 
Specifically, colorectal FFPE DNA was extracted by Dr. Donghui Zou. Colorectal 
FFPE sequencing libraries were prepared, sequenced, and analysed by Dr. Donghui 
Zou and Dr. Robert Day. The ddPCR primers and probes were designed by Dr. 
Donghui Zou and Judy Ann Cocadiz.  
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Primer design of the base and booster GI cancer panels was done in consultation with 
Dr. Andrew Cassidy. Design of the variant calling pipeline in the CLC Genomics 




3. CHAPTER 3: DESIGNING THE GASTROINTESTINAL 
CANCER PANEL 
3.1 Design Workflow 
A targeted DNA sequencing panel for GI cancers (the “GI cancer panel”) was designed 
with two main objectives in mind. Firstly, the panel was designed to capture both 
gastric and colorectal cancers. Proximal cancers of the gastroesophageal junction and 
distal oesophagus were also considered due to their close anatomic proximity to true 
gastric cancers. Secondly, sensitivity was maximised to ensure rare pathogenic 
mutations could be identified directly from plasma. This approach contrasts with many 
commercial sequencing panels, which query hundreds of genes to identify mutations. 
Whilst this has benefits in terms of sequencing a wide breadth of the genome, it comes 
at a cost of sequencing depth. As such, the GI cancer panel comprised only 21 genes 
with specialised oligonucleotide primers designed to increase the sensitivity of 
detecting rare pathogenic mutations in plasma.  
 
The GI cancer panel was designed in two phases. Firstly, genes frequently mutated in 
gastric and colorectal cancers were identified and manually curated to form a list of 
gene targets. Secondly, oligonucleotide primers were designed to cover these targets.    
 
The first design phase identified frequent mutations in gastrointestinal cancers to 
formulate a list of genes to be included in the panel. A more comprehensive process 
was employed to identify gastric cancer genes due to the lack of published evidence on 
dedicated gastric cancer sequencing panels. In contrast, colorectal cancer panels are 
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already commercially available, such as the QIAseq Targeted DNA Human Colorectal 
Cancer Panel (Qiagen, Germany) – so such a comprehensive process was not required 
to identify colorectal cancer genes. The manual curation of gastric cancer genes was 
done in a stepwise process whereby preliminary lists of genes were formulated and 
subsequently scrutinised.  
 
Details of the design process are described in chapters 3.2 and 3.3 and are briefly 
outlined as follows. Preliminary list A comprised the top 30 genes ranked by mutation 
frequency in a COSMIC gastric cancer dataset filtered to contain only pathogenic 
mutations (the “pathogenic dataset”).  Preliminary list B excluded preliminary list A 
genes that were not found in the Cancer Gene Census – a curated database describing 
genes that drive cancer (98). Preliminary list C was formed following the addition of 
frequently mutated genes in an unfiltered COSMIC gastric cancer dataset (the 
“unfiltered dataset”). The final list of gastric cancer genes was formed after cross-
referencing preliminary list C with mutations found in 20 published gastric cancer 
sequencing studies. 
 
Colorectal cancer genes were identified from existing colorectal sequencing data 
generated in the Cancer Genetics Laboratory. This data was produced from sequencing 
60 colorectal cancer patients using the QIAseq Targeted DNA Human Colorectal 
Cancer Panel (Qiagen, Germany) during 2018-2020 (62). A minimum subset of 




3.2 Identification of Gastric Cancer Genes 
3.2.1 Preliminary List A – Genes in the Pathogenic Dataset.  
Preliminary list A was generated by analysing version 91 of the COSMIC targeted 
screens, filtered for samples originating in the stomach. This dataset contained somatic 
mutations identified by targeted sequencing of 27,464 gastric cancer samples. Duplicate 
mutations originating from single samples were counted only once. Non-carcinoma  
(n = 1,740) and squamous cell carcinoma samples (n = 3) were excluded. To ensure 
only driver mutations were considered in this analysis, FATHMM predictions were 
used to exclude mutations not classified as pathogenic. The final pathogenic dataset 
contained 1,824 samples, including 165 gastroesophageal junction samples. The 
histological classifications of these 1,824 samples are outlined in Table 7.  
 
Table 7. Histological classifications of 1,824 gastric cancer samples in the pathogenic 
dataset.  
Histological Classification Number of Samples 
Adenocarcinoma 1,006 
Adenocarcinoma - unclassifiable 2 
Diffuse adenocarcinoma 207 
Fundic gland type adenocarcinoma 7 
Gastric type adenocarcinoma 1 
Intestinal adenocarcinoma 353 
Mixed adenosquamous carcinoma 2 
Mixed intestinal and diffuse adenocarcinoma – unclassifiable 32 
Mucinous adenocarcinoma 4 
Not specified 135 
Papillary adenocarcinoma 4 
Signet ring adenocarcinoma 16 
Small cell adenocarcinoma 1 
Tubular adenocarcinoma 38 





Mutation frequencies of the 599 genes in the pathogenic dataset were calculated by 
dividing the number of samples with mutations in each gene by the total number of 
samples in the dataset (n = 1,824). Due to the small number of samples, the absolute 
mutation frequency for each gene was not relevant; instead, the ranking of genes by 





Table 8. Preliminary list A - top 30 genes by mutation frequency in the pathogenic 
dataset. Frequencies were calculated by dividing the number of samples with mutations in each 
gene by the total number of samples in the pathogenic dataset (n = 1,824). Mutation frequencies 
are expressed as a proportion and rounded to 3 significant figures.  
Gene 
Rank in Pathogenic 
Dataset 




TP53 1 863 0.473 
KRAS 2 242 0.133 
PIK3CA 3 159 0.0872 
CTNNB1 4 90 0.0493 
CDH1 5 84 0.0461 
APC 6 71 0.0389 
RHOA 7 45 0.0247 
ERBB3 8 41 0.0225 
CREBBP 9 40 0.0219 
ARID1A 10 37 0.0203 
ERBB2 11 37 0.0203 
FBXW7 12 36 0.0197 
ERBB4 13 32 0.0175 
SMAD4 14 31 0.0170 
BRAF 15 28 0.0154 
GNAQ 16 28 0.0154 
PTEN 17 26 0.01423 
KMT2A 18 25 0.0137 
NF1 19 24 0.0132 
GNAS 20 23 0.0126 
NOTCH1 21 23 0.0126 
SMARCA4 22 23 0.0126 
TTN 23 23 0.0126 
MTOR 24 22 0.0121 
ATM 25 21 0.0115 
MED12 26 20 0.0110 
KMT2D 27 19 0.0104 
ATR 28 18 0.00987 
HRAS 29 18 0.00987 





3.2.2 Preliminary List B – Cross-Reference to the Cancer Gene Census.  
Preliminary list B was generated by excluding genes that were not reported in the 
Cancer Gene Census. Like FATHMM, the Cancer Gene Census describes the 
functional impact of genetic alterations to cancer. However, whilst FATHMM 
describes the functional impact of individual mutations, the Cancer Gene Census 
describes the role of entire genes in carcinogenesis, based on published evidence. The 
census classifies genes into one of two tiers. Tier one genes have documented evidence 
of both cancer-related functions and cancer-specific mutation patterns. Tier two genes 
have strong evidence for either cancer-related functions or cancer-specific mutation 
patterns (98). 
 
To ensure the final panel design contained true cancer drivers, only tier one genes were 
included in preliminary list B. 29 of the 30 preliminary list A genes were tier one genes 
however, the Titin (TTN) gene was not found in the Cancer Gene Census. With 363 
exons spanning over 280 kb, TTN is a large gene encoding the largest polypeptide in 
the human genome – a protein involved in muscle contraction (101). Many cancer 
sequencing studies have identified mutations in TTN, including gastric and 
gastroesophageal cancers (102-104). However, these high mutation rates are likely 
explained by the large size of TTN – increasing the chance of mutations occurring 
anywhere within its 280 kb length. In addition, the role of TTN in oncogenesis currently 




3.2.3 Preliminary List C – Cross-Reference to the Unfiltered COSMIC 
Dataset. 
Samples in the pathogenic dataset originated from published studies using exclusively 
targeted DNA sequencing approaches. As such, preliminary lists A and B were biased 
towards genes included in targeted sequencing panels. To reduce this bias, a dataset 
containing gastric cancer samples sequenced by both WGS and targeted approaches 
was utilised to identify frequently mutated genes. These genes were combined with 
preliminary list B – forming preliminary list C. Unlike the pathogenic dataset, variants 
in the unfiltered dataset were of all FATHMM classifications. Mutation frequencies 
were calculated by dividing the number of mutant samples for each gene by the total 
number of samples tested for each gene. To maintain consistency with preliminary list 
B, only genes in tier one of the Cancer Gene Census were considered. 15 genes with 
mutation frequencies above 10% were selected for inclusion (Table 9). TP53, CDH1, 
ARID1A, ERBB4, and KMT2D were found in both preliminary list B and at frequencies 
above 10% in the unfiltered dataset. The remaining 10 genes were combined with 






Table 9. Genes with mutation frequencies above 10% in the unfiltered dataset and in tier 
one of the Cancer Gene Census. Genes in bold are those that were not already found in 
preliminary list B. These were combined with preliminary list B to form preliminary list C. 
Mutation frequencies are expressed as a proportion and rounded to 3 significant figures. 
 
3.2.4 Final Gastric Cancer List – Cross-Reference of Preliminary List C to 
20 Published Sequencing Studies.  
The final gastric cancer gene list was formed by cross-referencing genes in preliminary 
list C against mutations reported in 20 published gastric cancer sequencing studies. This 
was done to ensure the COSMIC datasets used to generate preliminary lists A, B, and C 
were supported by independent studies by other investigators and sequencing 
approaches. The process of selecting these 20 studies is outlined in Chapter 2.1.4. A list 
of details for each study is displayed in Appendix 2. Only reported mutations were 
considered; copy number variations were ignored due to their inability of being 
detected by the GI cancer panel. Reported mutations in the 20 studies are displayed in 
Figure 3.






















Figure 3. Mutations of genes in preliminary list C reported in 20 published gastric cancer sequencing studies. Genes in bold are those included in the final gastric 
cancer gene list. Genes in red are those that were not present in preliminary list C but were included in the final gastric list due to their high mutation frequency in the 20 
study cohorts. ESO: mutations recorded in only oesophageal adenocarcinoma samples; GEJ: mutations recorded in only gastroesophageal junction adenocarcinoma 
samples; STO: mutations recorded in only gastric adenocarcinoma samples. 
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3.2.4.1 Studies Included in the Cross-Reference Analysis 
Whilst the absolute number of studies recording a mutation in each gene was 
considered during this cross-reference analysis, reported mutations in certain study 
cohorts were of more interest than others. Three studies were included due to their large 
sample sizes of between 215 and 387 gastric adenocarcinoma samples (12, 104, 105). 
Identified mutations in these three studies carried more weight than those found in 
smaller studies.  
 
A study that sequenced 44 peritoneal carcinomatosis samples was included to identify 
mutations common in patients with peritoneal metastases (106). As discussed 
previously, cancers that have disseminated to the peritoneum shed small quantities of 
ctDNA into the bloodstream (67). As such, it was imperative that genes mutated in the 
peritoneal carcinomatosis samples were included in the panel to increase capture rates 
of patients with peritoneal metastases. 
 
Two studies that directly sequenced plasma to identify pathogenic mutations in gastric 
cancer were included (75, 77).  One of these studies also sequenced matched white 
blood cells to distinguish pathogenic mutations from benign germline and CHIP-
associated variants (75). Consideration of these studies added confidence in the ability 
of the panel to identify mutations in ctDNA, whilst also highlighting genes impacted by 
CHIP.     
 
As the GI cancer panel was designed to prioritise sequencing depth over breadth, it was 
imperative that the small number of genes included in the panel were true cancer 
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drivers. To ensure this criterion was met, a study that identified genes under significant 
positive selection in gastric cancer was considered. This study used the normalized ratio 
of non-synonymous to synonymous mutations (dN/dS) to quantify selection of coding 
mutations in cancer-associated genes. Genes under positive selection carry more driver 
mutations than genes under negative selection and thus, are well-represented in their 
respective cancer types (107). Genes under positive selection in gastric cancers are 
considered true gastric cancer drivers and thus, were strong candidates for the GI 
cancer panel. 
 
Whilst gastric cancers commonly occur in the distal stomach, the GI cancer panel was 
designed to also capture proximal gastric cancers – including those of the 
gastroesophageal junction and distal oesophagus (8). To ensure these cancers could be 
identified, six studies that explicitly sequenced gastroesophageal junction cancers, in 
some instances alongside true gastric cancers, were included (77, 108-112). A seventh 
study which identified frequently mutated genes in oesophageal adenocarcinomas was 
also considered (113).  
 
Finally, to ensure the GI cancer panel could identify gastric cancers in a variety of 
ethnicities, study cohorts were selected from both Caucasian and Asian populations. 
Namely, one study compared mutation frequencies of 11 genes between Asian and 




3.2.4.2 Preliminary List C Genes Included in the Final Gastric Cancer List 
TP53 was the most frequently mutated gene in the 20 study cohorts – with all 20 
studies reporting at least one TP53 mutation (12, 75, 77, 103-119). SMAD4 was the 
second most common mutation, with mutations reported in 14 studies (12, 75, 77, 105-
111, 113-115, 118), followed by PIK3CA (12, 75, 77, 103, 105, 107, 109-111, 113, 
114, 117, 119), ARID1A (12, 77, 104, 105, 107-110, 113, 114, 116, 118, 119), and 
CDH1 (12, 75, 77, 106-108, 110, 111, 114, 115, 117-119) with reported mutations in 
13 studies each. In addition, KRAS (12, 75, 77, 105, 107, 109-111, 116-119), ERBB2 
(12, 75, 77, 105, 109-112, 116-119), and APC (12, 77, 105, 107, 109-111, 114-117, 
119) mutations were identified in 12 studies each. The eight aforementioned genes were 
all included in the final gastric cancer gene list due to their representation in over half 
of the 20 selected studies – including an occurrence in at least one of the three large 
study cohorts (12, 104, 105). They were also highly ranked in the pathogenic dataset – 
with TP53, ARID1A, and CDH1 mutations also occurring at high frequencies in the 
unfiltered dataset.  
 
The remaining preliminary list C genes were more closely analysed to determine their 
eligibility for the final gastric cancer gene list. PTEN, with mutations identified in ten 
studies (75, 77, 105, 107, 109-111, 114, 115, 118), was included in the final list. 
Importantly, PTEN mutations were successfully identified in both ctDNA studies (75, 
77), were reported in four of the seven gastroesophageal sequencing studies (77, 109-
111), and were enriched in Caucasian populations (114). Moreover, PTEN is under 
significant positive selection in gastric cancer (107) and mutations are frequently 
pathogenic – as indicated by its rank of 17 in the pathogenic dataset (Table 8).  
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With mutations in eight studies each, ATM (75, 77, 106, 108, 110, 111, 115, 117), 
CTNNB1 (12, 75, 77, 105, 111, 114, 116, 119) and FBXW7 (75, 77, 107, 110-112, 115, 
117) were also included in the final gastric cancer gene list. Of note, mutations in all 
three genes were identified in both ctDNA studies (75, 77), and collectively were found 
in four of the seven gastroesophageal studies (77, 110-112). CTNNB1 mutations were 
recorded in two of the three large study cohorts (12, 105), FBXW7 is under significant 
positive selection in gastric cancer (107), and ATM mutations are enriched in patients 
with peritoneal metastases (106). Finally, ATM, CTNNB1, and FBXW7 contained 
frequent pathogenic mutations – as indicated by their ranks of 25th, 4th, and 12th in the 
pathogenic dataset, respectively (Table 8). Overall, there was sufficient evidence to 
justify the inclusion of ATM, CTNNB1, and FBXW7 in the final gastric cancer gene list.    
 
RHOA mutations were observed in six study cohorts (12, 77, 106, 107, 116, 118). It 
was mutated in a large study cohort (12), is under positive selection in gastric cancer 
(107), and was identified in one of the ctDNA studies (77). In addition, RHOA was 
ranked 7th in the pathogenic dataset – corroborating its role in gastric carcinogenesis 
(Table 8). As such, RHOA was included in the final gastric cancer gene list.  
 
GNAS, with mutations in five studies (77, 106, 109-111), and BRAF, with mutations in 
four studies (75, 77, 111, 115) were excluded from the final gastric cancer gene list. Of 
the five studies reporting GNAS mutations, four were gastroesophageal sequencing 
studies, including a ctDNA study, and one was the peritoneal carcinomatosis study – 
highlighting the potential of GNAS to capture proximal gastric cancers and peritoneal 
metastases (77, 106, 109-111). However, GNAS was ranked 20th out of 30 in the 
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pathogenic dataset (Table 8), did not appear in the unfiltered dataset (Table 9), and 
mutations were not recorded in any of the large study cohorts (12, 104, 105). GNAS 
was therefore not included in the final gastric cancer gene list. Similarly, whilst BRAF 
mutations were identified in both ctDNA studies (75, 77), including one 
gastroesophageal study (77), it was ranked 15th out of 30 in the pathogenic dataset 
(Table 8), did not appear in the unfiltered dataset (Table 9), and mutations were not 
identified in any of the large study cohorts (12, 104, 105) – so was excluded from the 
gastric cancer list.  Whilst ATM was ranked lower than both GNAS and BRAF in the 
pathogenic dataset (Table 8), there was more evidence justifying its inclusion in the 
gastric cancer gene list. Mutations in ATM were reported in twice as many studies as 
BRAF and GNAS and were enriched in patients with peritoneal metastases and proximal 
gastric cancers – as discussed previously.  
 
Of the remaining six genes with identified mutations in four studies each (ERBB3, 
ERBB4, FAT4, LRP1B, NF1, and SMARCA4), only three were included in the final 
gastric cancer gene list – ERBB3 (105, 107, 116, 117), ERBB4 (75, 77, 111, 117), and 
LRP1B (103, 104, 116, 119). ERBB3 was included due to its mutation in a large study 
cohort (105), it being under positive selection in gastric cancers (107), and its 8th 
ranking in the pathogenic dataset (Table 8). Whilst ERBB4 was not significantly 
mutated in any of the three large study cohorts (12, 104, 105), it was ranked 13th in the 
pathogenic dataset (Table 8) and was also present in the unfiltered dataset at a 
frequency of 10.4% (Table 9). In addition, ERBB4 was identified in both ctDNA 
studies (75, 77) and as such, was included in the final list. LRP1B was also included 
due to its high mutation frequency in a large study cohort (104) and the unfiltered 
COSMIC dataset (Table 9) – both recording mutation frequencies of 29% .  
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Whilst FAT4, NF1, and SMARCA4 mutations were also identified in four of the 20 
study cohorts, supporting evidence was insufficient to justify their inclusion in the final 
gastric cancer gene list. FAT4, NF1, and SMARCA4 were not found in any of the large 
study cohorts (12, 104, 105), nor were they found in the peritoneal carcinomatosis 
study (106). Whilst NF1 was identified in a single ctDNA study (77) and both NF1 and 
SMARCA4 mutations were collectively identified in four gastroesophageal studies (77, 
108, 110, 112), both had low rankings, at 19th and 22nd respectively, in the pathogenic 
dataset (Table 8). As such, NF1 and SMARCA4 were excluded from the final gastric 
cancer gene list. A stronger case could have been made for FAT4 with mutation 
frequencies of 11% (105) and 25.8% (104) in two large study cohorts however, its 
absence in the pathogenic dataset (Table 8) warranted its exclusion. Whilst LRP1B was 
also absent in the pathogenic dataset but was included in the final list, it was the second 
most frequently mutated gene in the unfiltered dataset (Table 9). In summary, there was 
insufficient evidence to include FAT4, NF1, and SMARCA4 in the final gastric cancer 
gene list.  
 
In addition to the aforementioned genes, the final gastric cancer gene list also included 
CDKN2A, BRCA2, and EGFR – three genes not included in preliminary list C. Firstly, 
CDKN2A was included due to its mutation in eight study cohorts (77, 106, 109-111, 
113). Of note, five of the studies were gastroesophageal studies (77, 109-111) – 
suggesting inclusion of CDKN2A would increase the capture rate of proximal gastric 
cancers. In addition, CDKN2A mutations were reported in the peritoneal carcinomatosis 
study (106). Secondly, EGFR was included due to identified mutations in six studies 
(75, 77, 105, 117-119) – including one large study cohort (105) and one ctDNA study 
(75). Thirdly, BRCA2 was included due to its mutation in six studies (77, 106, 109, 110, 
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112, 115) – including the peritoneal carcinomatosis study (106) and four of the seven 
gastroesophageal studies (77, 109, 110, 112).  
 
The remaining 17 genes in preliminary list C did not have sufficient evidence to justify 
their inclusion in the final gastric cancer gene list. Mutations in each gene were 
reported in three or less published studies. None of the 17 genes were found in the three 
large study cohorts (12, 104, 105). Furthermore, none were under significant positive 
selection in gastric cancers (107). Whilst a few were identified in ctDNA or 
gastroesophageal studies, they were poorly represented in the pathogenic and unfiltered 
datasets (Tables 8 and 9).  
 
3.3 Identification of Colorectal Cancer Genes 
Gene targets for colorectal cancer were identified from existing colorectal sequencing 
data generated in the Cancer Genetics Laboratory (62). Pathogenic mutations were 
identified by searching the Varsome, COSMIC, and gnomAD databases – as outlined in 
chapter 4.1.3. All 60 patients contained a pathogenic mutation in at least one of four 
genes – APC, TP53, KRAS, and BRAF. In addition to these four genes, RNF43 was 
included in the colorectal list due to growing evidence of its role as an initiator of 
colorectal cancer and the presence of mutations in approximately 18% of colorectal 
cancers (120). In summary, APC, TP53, KRAS, BRAF, and RNF43 were selected to 
capture colorectal cancers. APC, TP53, and KRAS were already included in the final 




3.4 Final Gastrointestinal Cancer Panel Design  
Gastric and colorectal cancer genes were combined to give a final list of 21 gene targets 
for the GI cancer panel (Figure 4).  
 
Figure 4. Workflow of selecting the GI cancer panel gene targets. A. Selection of gastric 




3.5 Qiagen Targeted DNA Sequencing Panels  
Qiagen was selected to produce the GI cancer panel due to their utilisation of unique 
molecular indices (UMIs). UMIs are short sequences of DNA that tag each original 
sample molecule prior to amplification. During sequencing, UMIs are used to trace 
reads back to the original DNA molecules. Reads from different UMIs originate from 
different original molecules, whereas reads with the same UMIs are duplicates of a 
single original molecule. True mutations are those found in the majority reads within a 
UMI family (Figure 5A). False positives may arise due to amplification or sequencing 
errors but can be identified by their presence in only a small number of reads within a 
UMI (Figure 5A).  
 
During data analysis of sequencing data, variants are called by counting the number of 
UMIs they appear in, rather than counting the total number of reads. Singleton counts 
constitute instances where the variant was identified in only one molecule. Big counts 
constitute instances where the variant was identified in multiple amplicons with the 
same UMI. Each amplicon represents a duplicate of one original molecule (Figure 5B). 
Therefore, variants counted in big groups are more likely to be true than those counted 





3.6 Primer Design and Review 
Single gene-specific oligonucleotide primers were designed by Qiagen to cover exons 
of the GI cancer panel’s 21 target genes. Single gene-specific primers have distinct 
advantages over conventional dual primer approaches – which require two gene-
specific primers to anneal to target regions. In contrast, single primer extension 
approaches require only one gene-specific primer to anneal to each target region. 
During amplification, universal primers anneal to the opposite end of the DNA strand 
to generate amplicons of target regions (Figure 6).  
Figure 5. Principle of mutation detection using unique molecular indices (UMIs). A. Each 
original DNA molecule is tagged with a UMI and subsequently amplified. Mutations (red stars) 
found in the majority of reads within a UMI are likely true. Mutations found in a small number of 
reads within a UMI are likely errors arising during amplification or sequencing. B. During data 
analysis, variants are called by counting the number of UMIs they appear in. Singleton UMI 
counts constitute instances where the variant was read in only one molecule. Big UMI counts 
constitute instances where the variant was read in multiple amplicons with the same UMI (QIAseq 







ctDNA fragments are shorter and more irregular than gDNA and therefore, are more 
challenging for primers bind and generate reads. To mitigate these challenges, a high 
density of primers was tiled across target regions for both forward and reverse strands – 
thereby increasing the likelihood of primers annealing to the fragmented samples.  
 
.BED files representing the coverage of target regions were generated following the 
design of oligonucleotide primers. These files were analysed by the NCBI genome 
Figure 6. Qiagen Single Primer Extension Chemistry. Single gene-specific primers anneal to 
target regions during the target enrichment step of library preparations. Only one gene-specific 
primer anneals to each target region – increasing target coverage compared to dual-primer 
approaches. During PCR amplification, universal primers anneal to the opposite ends of DNA 
strands to generate reads of target regions (QIAseq Targeted DNA Sequencing Handbook, 
February 2020).  
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browser to identify regions with poor coverage. Tumour suppressor genes required 
extensive coverage of all regions due to the rarity of hotspot mutations within these 
genes (Figure 7A). In contrast, full-length coverage of oncogenes was less important 
due to the tendency of oncogenic mutations to be clustered at hotspots (Figure 7B). 
Regions poorly covered by primers were sent back to Qiagen for additional primer 
design. After several rounds of reviews, the final GI cancer panel design was confirmed 




Figure 7. Coverage of tumour suppressor and oncogenes by the GI cancer panel’s 
oligonucleotide primers. Black boxes represent the regions covered by oligonucleotide primers. 
Green boxes represent the exons of genes. A. Extensive coverage of tumour suppressor genes (e.g. 
APC) by oligonucleotide primers was required due to the rarity of hotspot mutations within these 
genes. B. Targeted coverage of oncogenes (e.g. KRAS) was sufficient due to the tendency of mutations 





4. CHAPTER 4: TESTING THE GASTROINTESTINAL 
CANCER PANEL 
4.1 Workflow 
As discussed in chapter 3.1, the GI cancer panel was designed to achieve two main 
objectives. Firstly, the panel must identify pathogenic mutations in colorectal and 
gastric cancers. Secondly, the panel must maximise sensitivity by deep sequencing of 
its 21 genes to identify rare pathogenic mutations. To test these two objectives, the GI 
cancer panel was firstly used to sequence colorectal FFPE and ctDNA samples. 
Secondly, a 100-oligonucleotide primer booster panel was designed to compensate for 
poorly performing primers and regions with low coverage in the colorectal samples. 
Finally, the base and booster panels were pooled together and used to sequence gastric 
ctDNA samples to identify pathogenic mutations.  
 
4.1.1 DNA Extractions  
High-quality DNA samples are required to achieve optimal analytical sensitivity of 
targeted sequencing panels – especially when used to sequence ctDNA samples. As 
discussed in chapter 1,2.4, gDNA contamination from white blood cells can lead to the 
misclassification of benign CHIP-associated variants as pathogenic mutations. To 
ensure high-quality DNA samples were used for sequencing, FFPE and ctDNA samples 




Figure 8 displays a typical bioanalyzer trace of a high-quality FFPE DNA sample. 
Fragment lengths vary between the tissue of origin and extraction kit used however, 
most colorectal FFPE fragments are well above 1,000 bp in length.   
 
Figure 9 displays a typical bioanalyzer trace of a high-quality ctDNA sample. Due to 
various factors such as ctDNA release mechanisms and nucleosome positioning, 
ctDNA fragments cluster at approximately 170 bp (54, 55). gDNA fragments from 
white blood cells are often much larger in size and are visualised by the presence of 
fragments from approximately 300 bp onwards (Figure 10).  
 
 





Blood collection and plasma separation are two factors influencing ctDNA yields and 
levels of gDNA contamination. Conventional EDTA tubes stabilise DNA for only up to 
six hours following blood collection (121). After six hours, DNA fragments start to 
become degraded – resulting in reduced ctDNA concentrations and increased gDNA 
contaminants. As such, plasma must be separated from blood collected into EDTA 
Figure 9. Bioanalyzer trace of a high-quality ctDNA sample with minimal gDNA 
contamination.   




tubes with minimal delays to ensure high-quality samples. Alternatively, specialised 
cfDNA blood collection tubes, such as Streck Cell-Free DNA BCTs (Streck, USA) and 
Roche Cell-Free DNA Collection Tubes (Roche, Switzerland), may be used to stabilise 
DNA for up to seven days before plasma separation is required (122).  
 
There were varying degrees of gDNA contamination in the colorectal and gastric 
ctDNA samples used in this study. Colorectal blood samples were collected into Roche 
Cell-Free DNA Collection Tubes (Roche, Switzerland) at Dunedin Hospital and plasma 
was separated within seven days of collection. In contrast, gastric blood samples were 
collected by collaborators at Seoul National University Hospital into EDTA tubes and 
plasma was separated within two hours of collection. Despite prompt plasma 
separation, gastric ctDNA samples still showed higher degrees of gDNA contamination 
than colorectal ctDNA – supporting the preferred use of specialised cfDNA blood 
collection tubes over EDTA tubes. Bioanalyzer traces of colorectal and gastric ctDNA 
samples are displayed in Appendix 3.  
 
Storage conditions of DNA samples also impacts the quality of ctDNA samples. A 
limited number of published studies reported no difference in DNA integrity between 
ctDNA samples stored as plasma or isolated DNA at -80°C (123-126). The QIAamp 
Circulating Nucleic Acids handbook states no preference other than to store ctDNA 
samples at -80°C if they will not be used on the same day as extraction (QIAseq 
Targeted DNA Sequencing Panel Handbook, February 2020). However, repeated 
freeze-thaw cycles have shown to hasten DNA degradation in both plasma and isolated 
DNA samples (123). Due to the availability of reagents and samples, colorectal ctDNA 
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samples used in this study were extracted the day before library preparations, whereas 
gastric ctDNA samples were extracted up to three months prior. Interestingly, up to a 
50% reduction in DNA concentrations was observed in samples stored for up to three 
months at -80°C – suggesting cell-free DNA may be more stable when stored as plasma 
compared to isolated DNA.  
 
4.1.2 Library Preparations 
During library preparations, each original DNA molecule was tagged with UMIs and 
various sequencing adaptors prior to amplification – generating sequencing libraries 
approximately twice the length of the starting fragments. Figure 11 outlines a high-
quality QIAseq library with fragment lengths of approximately 400 bp.  
 
Secondary and tertiary peaks shown in bioanalyzer traces represent the formation of 
secondary structures called “bubble products” (Figure 12). These form when primer 
availability is low due to high DNA inputs or PCR overamplification – both leading to 
the early consumption of sequencing primers. This causes complementary adapter 
sequences of non-complementary fragments to anneal to each other – resulting in the 
Figure 11. Bioanalyzer trace of a QIAseq library without overamplification. 
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formation of double-stranded products with partially open ‘bubbles’ in the middle of 
fragments. These bubble products are inconsequential as they are denatured into single-
stranded DNA fragments prior to sequencing.   
Figure 12. Bioanalyzer trace of QIAseq library with secondary and tertiary peaks 
comprised of “bubble products”. Bubble products form when there is a low availability of 
primers due to high DNA inputs or PCR overamplification. Bubble products are 
inconsequential as they are denatured prior to sequencing.  
 
All colorectal and gastric libraries prepared with the GI cancer panel showed secondary 
and tertiary peaks on the Bioanalyzer (Appendix 4) – indicating bubble products were 
formed. Whilst this could have been caused by PCR overamplification, the number of 
PCR cycles used for ctDNA samples was optimised by the manufacturer (Table 2). 
Furthermore, the number of PCR cycles used for FFPE samples was lower than 
recommended by the manufacturer (Table 2). Therefore, by elimination, these 
secondary structures formed due to too much DNA being used for library preparations.  
 
4.1.3 Identification of Pathogenic Mutations 
To distinguish pathogenic mutations from germline and CHIP-associated variants, 
mutations called by the Qiagen GeneGlobe Data Analysis Centre and the CLC 
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Genomics Workbench pipeline were subjected to several selection criteria. Firstly, 
mutations with frequencies of 0.45-0.55 and 0.8-1.00 were excluded due to their likely 
germline origins. Germline mutations do not reflect tumour dynamics and thus, are 
unsuitable ctDNA biomarkers. Remaining mutations were searched in Varsome and 
COSMIC databases. Those classified as benign or likely benign by Varsome, and 
neutral by COSMIC, were excluded as they were probably passenger mutations. 
Variants of uncertain significance, as classified by Varsome, were excluded if they 
were not classified as pathogenic by COSMIC, due to their equivocal role in 
carcinogenesis. Finally, mutations at high frequencies (>0.01%) in the general 
population were identified by the gnomAD database and subsequently excluded. 
Variants that passed all criteria were good ctDNA biomarkers that could be used to 
track tumour dynamics in plasma. The process of identifying pathogenic mutations 










4.2 Colorectal Cancer Samples 
4.2.1 Patient Details  
FFPE tissue and plasma samples from two colorectal cancer patients (M043 and M047) 
were selected for sequencing using the GI cancer panel. Both patients had stage 4 
colorectal cancer with liver metastases. FFPE tissue was collected prior to 
commencement of their chemotherapy regimens. Two cycles of plasma taken from 
each patient during chemotherapy treatment were also sequenced. The clinical details 
of M043 and M047 are outlined in Table 10.  
 
 
Figure 13. Process of identifying pathogenic mutations using Varsome, COSMIC, and 
gnomAD databases.  
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Table 10. Clinical information of two colorectal cancer patients treated with 
chemotherapy. Clinical information is presented as provided by the lead clinician. CAPEOX: 
























4.2.2 Identification of Pathogenic Mutations  
The GI cancer panel identified 14 pathogenic mutations in the two colorectal cancer 
patients (Figure 14). Eight mutations were identified in M043 and six were identified in 
M047 (Tables 11 and 12). APC, BRCA2, and TP53 mutations were identified in both 
patients. A single ERBB3 mutation was identified in M047, while PIK3CA and SMAD4 
mutations were only found in M043. The mutations found in each patient were unique 
aside from BRCA2 c.9097delA, which was found in both patients. Given that hotspot 
mutations are uncommon in tumour suppressor genes, the identification of the same 
BRCA2 mutation in both patients suggested that this variant might be a sequencing 







Table 11. Pathogenic mutations identified in M043 FFPE DNA (FF043) and ctDNA 
(M043C1 and M043C2) sequenced with the GI cancer panel. Frequencies are those reported 
by the GeneGlobe Data Analysis Centre. In instances where the mutation was not identified by 
this pipeline, frequencies are those reported by the CLC Genomics Workbench. SNV: single 
nucleotide variant; MNV: multiple nucleotide variant 
 
  
FF043 M043C1 M043C2 
APC c.905G>A 
Frequency: 3.50% 









Type: Non-Synonymous SNV 
APC c.3956delC 
Frequency: 31.7% 




Type: Non-Synonymous Deletion 
BRCA2 c.5073delA 
Frequency: 1.25% 




Type: Non-Synonymous Deletion 
BRCA2 c.9097delA 
Frequency: 3.02% 









Frequency: 58.6%  
Type: Non-Synonymous Deletion 
 
TP53 c.572delC 
Frequency: 2.38%  
Type: Non-Synonymous Deletion 
 PIK3CA c.1571G>A 
Frequency: 2.13% 
Type: Non-Synonymous SNV 
 
Figure 14. Pathogenic mutations found in two colorectal cancer patients. One FFPE 
(FF043; FF047) and two ctDNA (M043C1 and M043C2; M047C1 and M047C2) samples were 
sequenced per patient. Light-blue squares indicate the presence of a single pathogenic mutation. 
Dark-blue squares indicate the presence of two or more pathogenic mutations.  
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Table 12. Pathogenic mutations identified in in M047 FFPE DNA (FF047) and plasma 
(M047C1 and M047C2) sequenced with the GI cancer panel. Frequencies are those reported 
by the GeneGlobe Data Analysis Centre. In instances where the mutation was not identified by 
this pipeline, frequencies are those reported by the CLC Genomics Workbench. TP53 
c.524G>A was found at a typically germline frequency (48.8%) in FF047 – so was deemed an 
unsuitable ctDNA biomarker. However, this variant was called at frequencies below 10% in the 
two plasma cycles (M047C1 and M047C2) – so was deemed a suitable ctDNA biomarker. 
SNV: single nucleotide variant. 
 
Of the 14 pathogenic mutations identified by the GI cancer panel, 11 were identified in 
FFPE and ten were identified in plasma. Seven mutations were found in both FFPE and 
plasma. These seven mutations were found at higher frequencies in FFPE than in 
ctDNA – reflecting the dilution of ctDNA by normal cell-free DNA in the plasma 
(Tables 11 and 12). Of the 11 mutations identified in FFPE, four were not identified in 
either of the matched plasma cycles (Tables 11 and 12). Furthermore, five mutations 
were only identified in a single matched plasma cycle (Tables 11 and 12). APC 
c.4099C>T and TP53 c.524G>A, both found in M047, were the only two mutations 
identified in FFPE which were detected in both cycles of plasma (Table 12).  
 
FF047 M047C1 M047C2 
APC c.646C>T 
Frequency: 25.9% 
Type: Non-Synonymous SNV 
APC c.646C>T 
Frequency: 4.89% 




Type: Non-Synonymous SNV  
APC c.4099C>T 
Frequency: 3.06% 
Type: Non-Synonymous SNV 
APC c.4099C>T 
Frequency: 1.42% 
Type: Non-Synonymous SNV 
BRCA2 c.9097delA 
Frequency: 2.44% 




Type: Non-Synonymous SNV 
TP53 c.524G>A 
Frequency: 9.42% 
Type: Non-Synonymous SNV  
TP53 c.524G>A 
Frequency: 6.65% 
Type: Non-Synonymous SNV  
 BRCA2 c.1813delA 
Frequency: 2.10%  
Type: Non-Synonymous Deletion  
 
 ERBB3 c.2617-1dupG 
Frequency: 1.40%  




Interestingly, TP53 c.524G>A was found at a typically germline frequency of 48.8% in 
FFPE but dropped to frequencies below 10% in both plasma samples (Table 12). This is 
likely explained by the dilution of mutant ctDNA fragments by gDNA in the plasma. 
The drop in frequency to below 10% in both plasma cycles makes TP53 c.524G>A an 
unlikely germline variant and thus, probably reflects tumour dynamics.  
 
The absence of mutations observed in FFPE tissues in plasma can be explained by 
factors influencing the number of mutant DNA molecules available for detection. 
Firstly, less ctDNA was available for library preparations than FFPE DNA (Table 13). 
Secondly, FFPE samples represent relatively pure tumours, whereas ctDNA is diluted 
with variable amounts of normal cell-free DNA. These factors resulted in fewer mutant 
DNA molecules being available for detection in plasma samples compared to FFPE 
samples – thereby requiring higher sequencing depths to detect pathogenic mutations.   
 
There were also differences in the pathogenic mutations identified in the two plasma 
samples from each patient. The second plasma cycle of M043 (M043C2) and the first 
cycle of M047 (M047C1) harboured more pathogenic mutations than their respective 
first and second cycles. These discrepancies can again be explained by factors 
influencing the number of mutant ctDNA molecules available for detection. M043C2 
and M047C1 were collected at timepoints where the tumour burden appeared higher 
than when M043C1 and M047C2 were collected. This is evidenced by the higher 
ctDNA concentrations in M043C2 and M047C1 compared to M043C1 and M047C2, 
respectively (Figure 15). The apparently larger tumours at these timepoints shed more 
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ctDNA into the circulation, resulting in more mutant DNA molecules being present in 





Figure 15. Time of plasma collection for M043C1, M043C2, M047C1, and M047C2. 
M043C2 and M047C1 were collected at timepoints where the tumour burden appears to be 
higher than M043C1 and M047C2, respectively. The lower tumour burden at M043C1 and 




The loss and gain of mutations due to clonal evolution may also explain the 
discordance between the pathogenic mutations identified in different samples from the 
same patient. Due to the selection pressures of chemotherapy, certain mutations will be 
lost from the cancer gene pool whereas others will be gained over the course of 
treatment. This temporal heterogeneity may explain why mutations present in some 
samples are absent in others from the same patient. However, this explanation is 
unlikely for truncal mutations, such as APC, which are present in a large proportion of 
cancer cells due to their early occurrence in colorectal carcinogenesis. For these 
mutations, factors influencing the number of the mutant DNA molecules available for 
detection are more probable explanations for their absence in certain samples.  
 
4.2.3 Sequencing Performance  
All six colorectal samples (two FFPE and four ctDNA samples) were loaded onto one 
Miseq v2 300 cycle run. A summary of the quality control (QC) report for the 
sequencing run is provided in Table 13.  
Table 13. Quality control of the colorectal Miseq sequencing run. Colorectal FFPE DNA 
(FF043 and FF047) and ctDNA (M043C1, M043C2, M047C1, and M047C2) samples were 
loaded onto the same Miseq v2 300 cycle run. The table below summarises the run 
performance. Input DNA for Library Preparations: total amount of DNA used for library 
preparations; Total Reads: total number of sequencing reads; Output Groups: total number of 
UMI groups; Singleton Groups: number of UMI groups with only one read; Big Groups: 
number of UMI groups with more than one read; Average Reads Per Group: the mean number 

















FF043 75 ng 3,822,324 1,452,929 1,126,345 326,584 1.31 
M043C1 14.28 ng 8,483,288 2,073,711 1,210,551 863,160 2.02 
M043C2 30.15 ng 5,461,422 1,273,842 636,354 637,488 2.12 
FF047 78 ng 6,636,564 2,050,461 1,376,324 674,137 1.61 
M047C1 24 ng 4,674,618 870,005 397,280 472,725 2.66 




The DNA inputs for library preparations varied between samples (Table 13). A 75 ng 
target for FFPE DNA was set and reached for both FFPE samples. However, the 40 ng 
target for ctDNA was not reached in any of the four samples due to low plasma yields.  
 
Despite equimolar amounts (4 nM) of DNA libraries being loaded into the Miseq 
cartridge, the total number of reads varied per sample (Table 13). This variability can 
be explained by the errors in preparing and quantifying libraries. For example, the 
average length of DNA fragments was used to calculate the molarity of libraries. Using 
these averages may have led to errors in accurately quantifying each library, especially 
considering only fragments within the expected size distribution of Illumina libraries 
were used to calculate the library molarities – as outlined in chapter 2.4.2. In addition, 
measurement errors likely occurred whilst loading libraries, especially considering their 
small volumes, and would have contributed to the variability in the total number of 
reads between samples. Samples with higher total reads likely had more of their library 
loaded into the Miseq cartridge than those with lower total reads.  
 
UMI groupings indicate the sequencing depth of each sample. The total UMI groups 
represents the number of original molecules tagged with UMIs prior to amplification. 
As explained in chapter 3.5, singleton groups represent single reads of an original 
molecule whereas big groups comprise instances where an original molecule was read 
multiple times. The average reads per group shows the mean number of times each 
original molecule, or one of its amplicons, was read during sequencing. This value is a 
more universal indicator of sequencing depth than the total number of reads – which 
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can be skewed by molecules that are disproportionately read. As such, both FFPE 
samples (FF043 and FF047) were sequenced at lower depths than the four ctDNA 
samples (M043C1, M043C2, M047C1, and M047C2) (Table 13).  
 
4.2.4 Comparison of the GI Cancer Panel with a Commercial Colorectal 
Sequencing Panel  
Performance of the GI cancer panel was benchmarked against the commercial QIAseq 
Targeted DNA Human Colorectal Cancer Panel (Qiagen, Germany). FFPE DNA from 
M043 and M047 had been previously sequenced using this panel (62). To reduce 
tumour sampling bias, the same tubes of FFPE DNA used to test the commercial 
colorectal panel were used to test the GI cancer panel. DNA libraries were prepared 
using the same protocol (QIAseq Targeted DNA Sequencing Panel Handbook, 
February 2020.)  Sequencing data generated from both panels was analysed by the 
GeneGlobe Data Analysis Centre and pathogenic mutations were identified according 
to the process outlined in chapter 4.1.3. A list of pathogenic mutations identified in both 
panels is displayed is Tables 14 and 15. 
 
Table 14. Pathogenic mutations identified in M043 FFPE DNA (FF043) sequenced by the 
QIAseq colorectal panel and GI cancer panel.  The same tube of FFPE DNA was used for 
both sequencing runs. Variants were called by the GeneGlobe Data Analysis Centre. SNV: 
single nucleotide variant. 
FF043 – QIAseq Colorectal Panel FF043 – GI Cancer Panel 
APC c.3340C>T 
Frequency: 24.1% 
Type: Non-Synonymous SNV  
APC c.3340C>T 
Frequency: 33.7% 
Type: Non-Synonymous SNV  
 APC c.3956delC 
Frequency: 31.7% 
Type: Non-Synonymous Deletion  
TP53 c.572delC 
Frequency: 50.3% 
Type: Non-Synonymous Deletion  
TP53 c.572delC 
Frequency: 58.6% 




Table 15. Pathogenic mutations identified in M047 FFPE DNA (FF043) sequenced by the 
QIAseq colorectal panel and GI cancer panel.  The same tube of FFPE DNA was used for 
both sequencing runs. Variants were called by the GeneGlobe Data Analysis Centre. SNV: 
single nucleotide variant.  
FF047 – QIAseq Colorectal Panel FF047 – GI Cancer Panel 
APC c.646C>T 
Frequency: 29.1% 
Type: Non-Synonymous SNV  
APC c.646C>T 
Frequency: 25.9% 
Type: Non-Synonymous SNV 
APC c.4099C>T 
Frequency: 24.9% 
Type: Non-Synonymous SNV  
APC c.4099C>T 
Frequency: 23.6% 
Type: Non-Synonymous SNV  
ATM c.1345G>T 
Frequency: 1.26% 
Type: Non-Synonymous Deletion   
 
 
Both panels identified five unique pathogenic mutations in the two colorectal FFPE 
samples. Four mutations were concordant between the two panels. However,  
APC c.3956delC was identified exclusively by the GI cancer panel (Table 14) and  
ATM c.1345G>T was identified exclusively by the commercial panel (Table 15). 
Conclusions regarding the optimal sequencing panel could not be reached due to the 
small sample size and different sequencing depths however, the general concordance 
between the two panels was promising.  
 
4.2.5 Identification of Pathogenic Mutations by the GeneGlobe Data 
Analysis Centre and CLC Genomics Workbench  
Two different methods of variant calling were used when analysing the colorectal 
sequencing data. Firstly, variants were called using the GeneGlobe Data Analysis 
Centre. This online portal is the conventional method of variant calling recommended 
for QIAseq Targeted DNA Sequencing Panels. However, its lack of customisation 
makes it impossible to optimise variant calling for certain applications. Therefore, a 
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variant calling pipeline was created by Qiagen bioinformaticians for use in the CLC 
Genomics Workbench. This pipeline allowed the customisation of, among other 
variables, the lower frequency threshold at which variants were called. For the six 
colorectal samples sequenced using the GI cancer panel, variants were called down to 
1%. A comparison of variants called by both methods in the six colorectal samples was 
made and is outlined below, with detail provided in Appendix 6.  
 
All 12 variants called by the GeneGlobe Data Analysis Centre were also called by the 
CLC Genomics Workbench. In addition, the workbench identified ten variants that 
were not called by the GeneGlobe portal. These results highlighted apparent superiority 
in variant calling of the CLC Genomics Workbench, however, there was scepticism 
about the quality of variant calling. This scepticism stemmed from the workbench 
calling BRCA2 c.9097delA in both M043 and M047 (Tables 11 and 12). Whilst this 
mutation passed all the criteria of pathogenic mutations (Figure 13), it was peculiar that 
the same mutation was found in both patients. Mutations in tumour suppressor genes, 
such as BRCA2, occur throughout the gene and do not tend to cluster at hotspot sites – 
like mutations in oncogenes. Whilst it was possible that this mutation could have 
occurred in both patients, it seemed more likely that it arose from an error during PCR 
amplification or sequencing – especially considering its occurrence in an adenine 
mononucleotide repeat (Figure 16). However, this could not be confirmed without 
sequencing a high-quality gDNA control. If the mutation also occurred in the gDNA 
control, it probably originated from errors during PCR amplification or sequencing – 
suggesting the variant calling pipeline required added stringency to exclude such errors. 
Due to time constraints, a gDNA control could not be sequenced – so the variant calling 







Despite its questionable stringency, the CLC Genomics Workbench was the sole 
method of variant calling used for the gastric cancer plasma samples. However, a high-
quality gDNA control was sequenced alongside gastric samples to inspect the variant 
calling methods of the CLC Genomics Workbench.  
 
4.3 Design of a Booster Panel  
To further scrutinise the GI cancer panel, performance of the 2,752 oligonucleotide 
primers and coverage of the 21 genes of interest were assessed. A 100-primer booster 
panel was designed to compensate for poor performing primers and poorly covered 
regions. Approximately 50 primers were designed to compensate for the worst 
performing primers in the six colorectal samples. The remaining 50 primers were 
designed in regions with the poorest coverage across the six colorectal samples.   
 
4.3.1 Primer-Centric Approach  
To assess the performance of the 2,752 oligonucleotide primers, a “Primer Check” 
workflow was created in the CLC Genomics Workbench. This workflow counted 
coverage at bases immediately following the end of each primer. Sequencing coverage 
Reference Sequence 
Annotated Variant 
Figure 16. BRCA2 c.9097delA. This variant occurred in an adenine mononucleotide repeat and 
was identified in both M043 and M047. Mutations in tumour suppressor genes, such as BRCA2, 
do not tend to cluster at hotspot sites – meaning this variant was likely an artefact of PCR 
amplification or sequencing.    
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is highest in bases closest to primers – meaning counting coverage at bases immediately 
after each primer can be used as an indicator of primer performance. Poor performing 
primers generate few reads off the base immediately following it, whereas high 




Primer coverage was counted for all 2,752 primers in the six colorectal FFPE and 
ctDNA samples. Coverage values were divided by the total number of reads per sample 
– giving read-normalised values. The mean normalised coverage was calculated across 
the six colorectal samples and values were plotted as displayed in Figure 18.  
 
The absolute coverage and primer values displayed in Figure 18 are arbitrary. The 
curve of normalised primer coverage indicates primers performed variably. Primers 
along the linear part of the curve performed relatively consistently whilst primers at 
each end of the curve generated disproportionate numbers of reads. The ability of 
Figure 17. Method of determining primer performance by the “Primer Check” workflow. 




primers to anneal to DNA fragments and generate reads is determined by primer 
design, sample variability, and chance.  
 
Poorly designed primers will consistently generate low numbers of reads. Firstly, 
primers are designed to anneal to their target regions at an optimal temperature – based 
on the composition of nucleotides in each target region. Whilst this temperature is 
slightly different for each primer, only a single annealing temperature was used during 
target enrichment – meaning some primers bind more efficiently than others at this 
temperature. Secondly, primers may have complementary sequences to other primers in 
the panel, making them bind to each other rather than their target regions. These design 
factors will impact the same group of primers in each sample. In contrast, sample 
variability and chance will impact a different group of primers in each sequencing run. 
Firstly, annealing sites of primers were identified using the GRCh37 reference genome. 
However, the annealing sites in sample DNA are not identical to the reference genome 
due to patient-specific alterations occurring in these sites – making primers bind with 
variable affinities in each new sample. Secondly, primers may bind to their target 
regions with greater or lesser efficiencies due to chance.  
 
Therefore, the poorly performing primers identified in the colorectal samples were 
likely poorly designed (Figure 18). It is unlikely that sample variability and chance 
impacted the same group of primers each time in the six samples from two different 
patients. Although this could not be confirmed without testing primer performance in a 
high-quality gDNA control. Primers generating consistently low numbers of reads in a 
gDNA control are likely poorly designed and not due to sample variation. However, a 
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gDNA control could not be sequenced due to time constraints. Therefore, additional 
oligonucleotide primers were designed at sites close to the worst 50 performing 
primers, irrespective of the reason causing their poor performance.  
 
4.3.2 Region-Centric Approach 
Target regions of the GI cancer panel covered at depths of less than 100x were flagged 
for redesign. Similarly, regions with poor coverage could have arisen due to poorly 
designed primers, sample variability, or chance. Again, this could not be determined 
without the use of a gDNA control. In the absence of such a control, regions with low 
coverage in more than one sample were submitted for redesign. 13 regions met this 
Figure 18. Normalised primer coverage in FFPE and ctDNA samples from two colorectal 
cancer patients. The mean primer coverage across six colorectal samples (two FFPE and four 
ctDNA samples), normalised for the number of reads, is plotted. The absolute coverage and 
primer numbers are arbitrary. Primers along the linear portion of the curve performed relatively 
consistently. Primers at the ends of the curve generated disproportionate numbers of reads. This 
could be due to primer design, sample variability, or chance. 50 primers were designed at sites 
close to the 50 worst performing primers.   
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criterion (Table 16). Approximately 50 primers were designed to cover these 13 
regions.  
Table 16. Regions covered at a depth of less than 100x in more than two colorectal 
samples sequenced by the GI cancer panel. 50 primers were designed to cover these regions 
in the booster GI cancer panel.  
Gene Chromosome Region Start Region Stop 
ARID1A 1 27022885 27022934 
ARID1A 1 27022963 27022976 
ARID1A 1 27023030 27023039 
ARID1A 1 27023779 27023788 
ARID1A 1 27023955 27024006 
ARID1A 1 27024031 27024046 
LRP1B 2 141081452 141081467 
PIK3CA 3 178937843 178937850 
ATM 11 108119645 108119656 
BRCA2 13 32918680 32918700 
BRCA2 13 32918769 32918781 
PTEN 10 89623706 89624306 
RHOA 3 49398361 49398500 
 
The resultant 100-primer booster panel was pooled with the 2,752-primer base panel 
and used to sequence ten gastric ctDNA samples to identify pathogenic mutations.  
 
4.4 Gastric Cancer Samples  
4.4.1 Patient Details  
Plasma samples from ten gastric cancer patients were sequenced to identify pathogenic 
mutations. Plasma was collected prior to treatment. Patients GC101-GC108 had stage 
1-4 cancers and were scheduled to have their tumours surgically resected (Table 17). 
Patients GC201 and GC202 had unresectable stage 4 cancers and were scheduled to 




Table 17. Clinical information of eight gastric cancer patients treated with surgery. 
Clinical information is presented as provided by the Seoul National University Hospital. 
 
 
Table 18. Clinical information of two metastatic gastric cancer patients treated with 
chemotherapy. Clinical information is presented as provided by the Seoul National University 
Hospital. MEDIOLAPAC: Durvalumab, Olaparib, and Paclitaxel; FOLFOX: Folinic acid, 
Fluorouracil, Oxaliplatin; BGB-A317-305: Tislelizumab, Oxaliplatin, Capecitabine or 
Cisplatin, and Fluorouracil. 
 
 







Location of Distant 
Metastases 
GC101 62 M 1A pT1aN0 Intestinal -  
GC102 50 M 3B pT2N3b Diffuse -  
GC103 67 M 3B pT3N3a Intestinal -  
GC104 68 M 4 -  -  Peritoneum 
GC105 56 M 2B pT2N2 Intestinal -  
GC106 69 M 2B pT2N2 Intestinal -  
GC107 54 F 1A pT1aN0 Diffuse -  
GC108 53 M 1A pT1bN0 Diffuse -  























4.4.2 Sequencing Performance 
ctDNA samples from all ten patients were loaded onto one Miseq v2 300 cycle run, 
alongside a gDNA control – totalling 11 samples on one run. To achieve the desired 
sequencing depth within the time available, a total of six sequencing runs were 
performed in series. After each run, variants were called using the CLC Genomics 
Workbench pipeline from output .fastq files. Successive runs were processed with 
previous runs – resulting in the collation of sequencing reads with each new run. In 
effect, this strategy produced the desired sequencing depth without the need to ship 
samples out of Dunedin for sequencing on a larger platform. Due to time constraints, 
results of only the first four sequencing runs will be discussed in this thesis. A summary 
of the collated QC reports from the first four runs is outlined in Table 19.  
 
Table 19. Performance of the Gastric Miseq Sequencing Runs. Gastric ctDNA samples 
were loaded onto the same Miseq v2 300 cycle runs. The table below summarises the 
performance of the first four runs. Input DNA: total amount of DNA used for library 
preparations; Total Reads: total number of sequencing reads; Output Groups: total number of 
UMI groups; Singleton Groups: number of UMI groups with only one read; Big Groups: 
number of UMI groups with more than one read; Average Reads Per Group: the mean number 

















GC101 50.8 ng 17,358,734 3,329,776 1,625,098 1,704,678 2.59 
GC102 12.5 ng 13,350,832 1,255,421 731,183 524,238 5.21 
GC103 40.0 ng 13,126,956 2,835,444 1,487,361 1,348,083 2.28 
GC104 30.8 ng 16,465,616 2,249,756 1,010,897 1,238,859 3.60 
GC105 18.6 ng 14,876,788 2,196,582 1,020,950 1,175,632 3.31 
GC106 16.9 ng 14,579,064 1,119,466 644,645 474,821 6.38 
GC107 18.4 ng 13,521,862 1,608,425 768,391 840,034 4.05 
GC108 13.7 ng 11,886,532 1,324,861 657,320 667,541 4.41 
GC201 36.3 ng 12,233,594 2,708,966 1,328,258 1,380,708 2.24 
GC202 27.3 ng 10,107,248 2,056,463 998,807 1,057,656 2.44 
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As was found in the colorectal FFPE and ctDNA samples, there was a discrepancy in 
the total number of reads per sample (Table 19) – likely explained by errors in 
preparing and quantifying libraries. These errors are discussed in detail in chapter 4.2.3.  
 
As indicated by the average reads per UMI group (Table 19), overall, these gastric 
samples were sequenced deeper than the colorectal samples sequenced with only one 
Miseq run (Table 13). GC106 was sequenced at the highest depth, with 6.38 average 
reads per UMI group, and GC201 was sequenced at the lowest depth, with 2.24 average 
reads per UMI group.  
 
4.4.3 Variant Calling Using the CLC Genomics Workbench  
Variants were called using the CLC Genomics Workbench pipeline. In the first three 
runs, variants were called down to 1%. However, variants were called down to 0.5% in 
the fourth run due to the disappearance of a previously identified pathogenic BRAF 
mutation (BRAF c.1208delC) in GC201 (Supplementary Table 10). This variant 
occurred at a frequency of 1.12% in the first run but was undetectable in the second and 
third runs - suggesting its absence was due to it falling below the lower detection limit 
of the variant calling pipeline.  When the lower detection limit was reduced to 0.5%, 
this variant re-emerged at a frequency of 0.55%.  
 
However, upon dropping the lower detection limit, a BRCA2 mutation (BRCA2 
c.8940delA) identified in the third run of GC201, at a frequency of 1.21%, became 
undetectable in the fourth run (Supplementary Table 10). This variant was initially 
called at a frequency of 0.87% in the fourth run but did not pass all variant calling 
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filters and thus was absent from the final variant list. This is likely explained due to its 
low number of reads. BRCA2 c.8940delA was read only nine times out of a region that 
was covered 1033 times. Of these nine reads, eight were singleton counts and one was a 
big count (Table 20). In addition, this mutation deleted an adenine nucleotide in an 
adenine mononucleotide repeat - suggesting it could be an artefact of PCR 
amplification or sequencing and not a true pathogenic mutation. Contrary to this idea, 
this BRCA2 variant was not identified in the gDNA control (Appendix 7). Therefore, 
further investigation is required to determine the suitability of BRCA2 c.8940delA as a 
ctDNA biomarker in GC201.  
 
Table 20. Mutation frequency of BRCA2 c.8940delA found in GC201 ctDNA. BRCA2 
c.8940delA was identified in the third run of GC201 but did not pass all variant calling filters in 
the fourth run – despite it occurring at a frequency above the lower detection limit. The variant 
was only counted 9 times in a region covered 1033 times. Furthermore, it involved the deletion 
of an adenine nucleotide in an adenine mononucleotide repeat – suggesting it might be an 
artefact of PCR amplification or sequencing. However, this variant was not identified in the 
gDNA control – which is typical of PCR and sequencing artefacts. Therefore, further 
investigation is required to determine the suitability of BRCA2 c.8940delA as a ctDNA 
biomarker. 
GC201 Run 1 GC201 Run 2 GC201 Run 3 GC201 Run 4 
  BRCA2 c.8940delA 
Frequency: 1.21% 
Total UMI Counts: 11 
Singleton Counts: 10 




Total UMI Counts: 9 
Singleton Counts: 8 
Big Counts: 1 
Coverage: 1033 
 
To determine the stringency of variant calling by the CLC Genomics Workbench, a 
high-quality gDNA control was sequenced alongside the ten gastric ctDNA samples. 
Six variants (Appendix 7) were identified in both ctDNA samples and the gDNA 
control – representing amplification or sequencing artefacts. Therefore, added 
stringency in variant calling methods is required for the CLC Genomics Workbench 
pipeline to exclude these errors in future samples.  
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4.4.4 Identification of Pathogenic Mutations 
True pathogenic mutations were identified in the plasma of eight out of the ten gastric 
cancer patients. GC104, a patient with stage 4 cancer with peritoneal metastases, and 
GC105, a patient with stage 2B intestinal-type gastric cancer, had no detectable 
pathogenic mutations in their ctDNA. In the remaining eight patients, a total of 33 
unique pathogenic mutations were detected in 15 of the 21 genes in the GI cancer 
panel. BRCA2 and ERBB2 were the most frequently mutated genes – with identified 
mutations in four patients each. ATM, ERBB3, and TP53 were the next most common – 
with identified mutations in three patients each. BRAF, ERBB4, LRP1B, and PIK3CA 
mutations were identified in two patients each, followed by ARID1A, CDH1, CDKN2A, 
CTNNB1, EGFR, and KRAS, which were each identified in only one patient (Figure 
19).   
 
 
Figure 19. Pathogenic mutations identified in the plasma of ten gastric cancer patients. 
Light blue squares represent the presence of a single pathogenic mutation. Dark blue squares 
represent the presence of two different pathogenic mutations.  
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Interestingly, BRCA2 and ERBB2 mutations were more common in this Korean cohort 
than in other published gastric cancer cohorts. BRCA2 and ERBB2 were found in 7.3% 
and 4.5%, respectively, of samples in the large unfiltered dataset, compared to 40% of 
patients in this cohort. Whilst a direct comparison cannot be made due to the small size 
of this Korean cohort, this finding suggests that mutations in these genes may be more 
common than previously thought. Furthermore, TP53 was not the most frequently 
mutated gene in this cohort – which is contrary to the well-established reports of TP53 
being the most frequently mutated gene in gastric cancers (12).  
 
There appeared to be a correlation between certain mutations and Lauren subtypes. 
CDH1, a known driver of diffuse gastric cancer, was mutated in GC202, a patient with 
stage 4 diffuse gastric cancer at a frequency of 12.2% (Supplementary Table 11). 
However, CDH1 mutations were not identified in any of the other diffuse gastric 
cancers (GC102, GC107, and GC108). ERBB4, PIK3CA, ARID1A, and CDKN2A 
mutations occurred exclusively in diffuse gastric cancers. ERBB4 mutations were found 
in GC102 and GC107 at frequencies of between 0.59% and 1.46% (Supplementary 
Tables 3 and 8). PIK3CA mutations were identified in GC102 and GC202 at 
frequencies of 2.28% and 1.01%, respectively (Supplementary Tables 3 and 11). 
Finally, ARID1A and CDKN2A mutations were both identified in GC102 at frequencies 
of 1.24% and 1.10%, respectively (Supplementary Table 3).  
 
 In contrast, BRAF, LRP1B, CTNNB1, EGFR, and KRAS mutations were found only in 
intestinal gastric cancers. BRAF mutations were identified in GC101 and GC201 at 
frequencies of 0.61% and 0.54%, respectively (Supplementary Tables 2 and 10). 
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LRP1B mutations were identified in GC106 and GC201 at frequencies between 0.60% 
and 1.50% (Supplementary Tables 7 and 10). Finally, CTNNB1, EGFR, and KRAS 
mutations were identified in one patient each at frequencies of 0.96%, 1.08%, and 
0.61%, respectively (Supplementary Tables 7 and 9). Whilst these correlations between 
mutated genes and the Lauren classification are not conclusive due to the small sample 
size, they highlight potential enrichments with histological subtypes that should be 
further investigated.  
 
There was variability in the number of pathogenic mutations identified in the ten gastric 
cancer patients. This variability did not appear to correspond with clinicopathological 
features, such as cancer stage.  GC102, a patient with grade 3B diffuse cancer, 
harboured the most pathogenic mutations. Nine unique mutations were identified in 
eight different genes (Supplementary Table 3). Seven unique mutations in six different 
genes were identified in GC106, a patient with grade 2B intestinal cancer 
(Supplementary Table 7). GC201 and GC202 harboured the next highest number of 
pathogenic mutations, with each patient possessing six and four mutations, respectively 
(Supplementary Tables 10 and 11). Interestingly, GC101, GC107, and GC108, three 
patients with stage 1 cancers, harboured two to three pathogenic mutations each 
(Supplementary Tables 2, 8, and 9). In contrast, GC104 and GC105, two patients with 
stage 3 and 4 cancers respectively, possessed no pathogenic mutations (Supplementary 
Tables 5 and 6). This finding of more pathogenic mutations in three early-stage cancers 
compared to two late-stage cancers was unexpected but could be explained by both 
biological and sequencing factors – such as differences in the degree of tumour 




As was expected, the number of pathogenic mutations identified in each patient grew 
with increasing numbers of reads and UMI sequencing depths. As such, it is to be 
expected that even more pathogenic mutations will be identified in the fifth and sixth 
sequencing runs.  
 
4.5 Performance of the Base and Booster GI Cancer Panel  
4.5.1 Primer Performance 
The 2,852 oligonucleotide primers in the combined base and booster GI cancer panel 
were analysed using the same “Primer Check” tool used to analyse primers in the base 
panel alone, as described in chapter 4.3.1. The mean normalised coverage was 
calculated across the ten gastric samples after the fourth sequencing run and values 
were plotted as displayed in Figure 20.  
 
The normalised primer coverage curve generated from the combined base and booster 
panel in gastric ctDNA samples (Figure 20A) was similar to that generated in the 
gDNA control (Figure 20A) and colorectal cancer samples sequenced with the base 
panel alone (Figure 18). Primers along the linear portion of the normalised coverage 
curves performed relatively consistently. However, the ends of the curves represent 
primers that generated disproportionately high and low numbers of reads. As discussed 
in chapter 4.3.1, this may have occurred due to poor primer design, sample variability, 
or chance. To distinguish poorly designed primers from those impacted by sample 
variability and chance, the worst 50 primers in the gastric ctDNA and gDNA control 
were identified (Figure 20C and 20D). Of the 50 worst primers in each sample type, 33 
were shared by both sample types. These 33 primers could not anneal to their target 
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regions in the ctDNA samples and the high-quality gDNA control – suggesting their 
poor performance was due to design and not sample variability. Furthermore, it is 
unlikely the few reads generated by these 33 primers can be explained by chance. 30 of 
these primers originated from the base GI cancer panel – representing the same primers 
that performed poorly in the colorectal samples (Figure 18). Whilst these primers 
cannot be removed from the GI cancer panel, the majority of the booster panel primers 








 A B 
C D 
Figure 20. Normalised primer coverage in ctDNA samples from ten gastric cancer patients and a gDNA control. The read-normalised primer coverage 
in ten gastric cancer ctDNA samples (A) and a gDNA control (B) are plotted above. The absolute coverage and primer numbers are arbitrary. Primers along 
the linear portion of the curves performed relatively consistently. Primers at the ends of the curves generated disproportionate numbers of reads. C and D 
show the worst 50 primers in the gastric ctDNA samples and the gDNA control. 33 primers (shown in red) performed poorly in both sample types – 




4.5.2 Region Performance 
Coverage of the 21 genes of interests by the combined base and booster panel was 
analysed using the same method as outlined in chapter 4.3.2. Only two regions were 
covered at a depth of less than 100x in two or more samples (Table 21). These regions 
were not poorly covered in the gDNA control – suggesting the reason for poor coverage 
is sample variability and not primer design.  Compared to the base panel alone, the lack 
of poorly covered regions indicates the vast improvement in target region coverage of 
the combined base and booster panels.  
 
Table 21. Regions covered at a depth of less than 100x in more than two gastric samples 
sequenced by the GI cancer panels (base and booster). Importantly none of the two regions 
were poorly covered in the gDNA – suggesting that the reason for poor coverage is poor sample 
quality. 
Gene Chromosome Region Start Region Stop 
ARID1A 1 27022855 27022855 
ARID1A  1 27022885 27022885 
 
4.6 Summary of Findings 
In summary, the GI cancer panel successfully identified pathogenic mutations in the 
plasma of gastric and colorectal cancer patients. 13 unique pathogenic mutations in six 
genes were identified in both colorectal cancer patients, and 33 unique pathogenic 
mutations in 15 genes were identified in eight of the ten gastric cancer patients. 
Variants were successfully called down to 0.5% - indicating the panel met its objective 
of maximising sensitivity to detect rare pathogenic mutations in the plasma of gastric 




5. CHAPTER 5: MONITORING TUMOUR SUPPRESSOR 
AND ONCOGENIC MUTATIONS IN COLORECTAL 
ctDNA 
5.1 Background 
Following identification of pathogenic mutations by sequencing, ddPCR assays can be 
used to track the concentrations of selected mutations in plasma overtime. Serial 
monitoring of pathogenic mutations is cheaper and faster using ddPCR assays than 
sequencing approaches. However, ddPCR surveillance requires an optimised PCR 
assay for each mutation of interest, thereby limiting the breadth of genomic 
interrogation to a small number of loci. Careful consideration is required when 
selecting variants for surveillance, as mutation concentrations may not always be 
representative of the entire tumour genome due to the loss and gain of mutations 
overtime.   
 
In colorectal cancers, mutations in tumour suppressor genes are common truncal events 
and thus, are harboured by a large proportion of cancer clones (17, 29). As such, it was 
hypothesised that mutations in major tumour suppressor genes, such as APC and TP53, 
would serve as more accurate biomarkers of the tumour burden than mutations in 
oncogenes, which are more likely to occur later in colorectal carcinogenesis. To explore 
this hypothesis, ddPCR assays were designed for tumour suppressor mutations 
identified in six colorectal cancer patients treated with chemotherapy. These patients 
already had an oncogenic mutation tracked in their plasma (62). Performance of the two 
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mutation types were compared to see whether tumour suppressor mutations detected a 
higher tumour burden than mutations in oncogenes.  
 
5.2 Patient Details  
Six colorectal cancer patients were used for the purposes of this study. Patients had 
previously received surgery to remove their tumours and were receiving adjuvant 
chemotherapy at the time of plasma collection. Serial plasma cycles were collected 
throughout the treatment course for the purposes of tracking mutations by ddPCR. A 
summary of the patient characteristics is outlined in Table 22.  
 
Table 22. Clinical information of six colorectal cancer patients treated with 
chemotherapy. Clinical information is presented as provided by the lead clinician. CAPE: 
















M006 73 M 3 
Complete 
Resection 
-  CAPE 













M034 83 M 3 
Complete 
Resection 
-  CAPE 




M050 79 M 4 
Measurable 
Disease 





5.3 Digital Droplet PCR Assay Design and Optimisation  
Each of the six patients already had a pathogenic mutation in an oncogene tracked by 
ddPCR in a study conducted by the Cancer Genetics Laboratory (62). In this study, 
mutations were identified by sequencing FFPE samples using the QIAseq Targeted 
DNA Human Colorectal Cancer Panel (Qiagen, Germany). Individualised ddPCR 
assays were designed to track oncogenic mutations in the plasma. For the current study, 
an additional tumour suppressor mutation was selected for each patient and tracked in 
the plasma using ddPCR. Assays for the tumour suppressor mutations had already been 
designed by Dr. Donghui Zou and Judy-Ann Cocadiz prior to the commencement of 
this study.  
 
Optimisation of each assay was done using gradient ddPCR to determine the optimal 
melting temperature for each assay. The temperature displaying the best separation of 
positive and negative droplets in both ctDNA samples and normal gDNA controls was 






5.4 Monitoring Tumour Suppressor and Oncogenic Mutations 
in the Plasma of Colorectal Cancer Patients 
Of the six tumour suppressor mutations selected for follow-up, three were APC 
mutations and three were TP53 mutations. Concentrations of tumour suppressor and 
oncogenic mutations in each of the six colorectal cancer patients are displayed in 






Figure 21. Optimisation of ddPCR assays using gradient PCR. The optimal melting 
temperature of each assay was determined by the temperature at which positive droplets (high 
amplitudes) were best separated from negative droplets (low amplitudes) in both ctDNA 
samples (C) and normal gDNA controls (N). Blue droplets represent mutant probes whereas 






Figure 23. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M018 
throughout treatment. TP53 is the tumour suppressor mutation and BRAF is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CEA: carcinoembryonic 
antigen; CT: computed tomography; FOLFIRI: folinic acid, fluorouracil, and irinotecan. 
Figure 22. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M006 
throughout treatment. APC is the tumour suppressor mutation and KRAS is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CAPE: capecitabine; CEA: 




Figure 25. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M034 
throughout treatment. TP53 is the tumour suppressor mutation and BRAF is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CAPE: capecitabine; CEA: 
carcinoembryonic antigen; CT: computed tomography.  
Figure 24. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M027 
throughout treatment. TP53 is the tumour suppressor mutation and BRAF is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CEA: carcinoembryonic 
antigen; CT: computed tomography; FOLFOX: folinic acid, fluorouracil, and oxaliplatin; FOLFIRI: 




Figure 26. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M045 
throughout treatment. APC is the tumour suppressor mutation and PIK3CA is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CAPEOX: capecitabine and 
oxaliplatin; CEA: carcinoembryonic antigen; CT: computed tomography. 
Figure 27. Serial ctDNA surveillance of tumour suppressor and oncogene mutations in M050 
throughout treatment. APC is the tumour suppressor mutation and KRAS is the oncogenic 
mutation. The concentration of mutations in ctDNA are expressed as the number of mutant copies 
per mL of plasma. Serial CEA assays are displayed as a comparison. CAPEOX: capecitabine and 
oxaliplatin; CEA: carcinoembryonic antigen; CT: computed tomography. 
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Mutations in tumour suppressor genes and oncogenes were detected in all six patients. 
The concentrations of each mutation type fluctuated throughout treatment courses – 
reflecting the dynamic changes in tumour burden. M018 and M027, two patients with 
stage 4 colorectal cancers and concomitant liver metastases, had the highest detectable 
levels of ctDNA – with concentrations as high as 1,400 mutation copies/mL plasma in 
M018 (Figure 23) and 2,000 mutation copies/mL plasma in M027 (Figure 24). In 
contrast, M006, M045, and M050 produced less than 5 mutant copies/mL of ctDNA in 
all plasma cycles analysed (Figures 22, 26, and 27).  
 
ctDNA concentrations correlated well with radiographic imaging studies in some 
instances. For example, concentrations of BRAF c.1799T>A and TP53 c.637C>T found 
in M027 (Figure 24) increased on days 49 and 63 of treatment with the FOLFOX 
chemotherapy regimen. This increase suggested disease progression – which was 
subsequently confirmed on day 71 by a CT scan. However, ctDNA concentrations 
contradicted CT scans in other instances. For example, in M034 (Figure 25), CT scans 
identified no signs of tumour recurrence on day 237 and day 250 of treatment, however 
concentrations of both BRAF c.1799T>A and TP53 c.514G>T rose from approximately 
30 copies/mL on day 167 to above 100 copies/mL on day 253 – suggesting the patient 
developed recurrence.  
 
Comparing tumour suppressor and oncogenic mutations yielded mostly consistent 
results. The highest concordance between the two mutation types was observed in 
M018 (Figure 23). In this patient, the oncogenic BRAF c.1799T>A mutation and 
tumour suppressor TP53 c.586C>T mutation were more than 90% similar in all four 
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plasma cycles. The BRAF mutation was found at higher concentrations in three of the 
four plasma cycles. This consistency suggested both mutations were found at similar 
frequencies in the dominant clonal population. Similar concordance between the two 
mutation types was found in M027 (Figure 24), M034 (Figure 25), and M050 (Figure 
27). Concentration trends were consistent throughout the course of treatment in all three 
patients. However, the absolute concentrations of the two mutation types differed in 
each patient. In M027, the tumour suppressor mutation (TP53) was found at higher 
concentrations than the oncogenic mutation (BRAF) in all plasma cycles. This implies 
the presence of two distinct subclones harbouring each mutation, with the BRAF 
subclone being more sensitive to the FOLFOX treatment (Figure 24). The opposite was 
found in M034. The tumour suppressor mutation (TP53) was found at higher 
concentrations than the oncogenic mutation (BRAF) in the last two plasma cycles – 
suggesting the BRAF subclone was more rapidly proliferative than the TP53 subclone 
in the absence of capecitabine (Figure 25). In M050, the oncogenic mutation was higher 
in the first cycle of plasma but dropped below the tumour suppressor mutation in the 
second cycle. Neither mutation was detected in subsequent plasma cycles (Figure 27).  
 
Mutations in tumour suppressor genes and oncogenes diverged in both M006 and 
M045. In M006, the tumour suppressor mutation (APC c.4308delT) was detectable in 
only one plasma cycle collected on day 205 (Figure 22). In contrast, the oncogenic 
mutation (KRAS c.436G>A) was detected in three plasma cycles, collected on days 
100, 205, and 349. In M045, the oncogenic mutation (PIK3CA c.1624G>A) was 
detectable in only one cycle of plasma collected on day 149. In contrast, the tumour 
suppressor mutation (APC c.1495C>T) was detected in six plasma cycles, collected on 
days 22, 48, 93, 139, 149, and 170 (Figure 26). However, this divergence between 
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tumour suppressor and oncogene mutations was small and therefore, probably reflects 
slight differences in the sensitivities of ddPCR assays rather than differences in clonal 
dynamics.  
 
Although sample numbers were small, this study has found no evidence to suggest 
tumour suppressor genes are better ctDNA biomarkers than oncogenes. However, it has 
provided evidence of tumour heterogeneity in a subset of the tumours. This observation 
highlights the importance of following more than one ctDNA biomarker in longitudinal 
patient surveillance.   
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6. CHAPTER 6: DISCUSSION 
Gastrointestinal cancers are significant contributors to the cancer burden both globally 
and in New Zealand. Gastric and colorectal cancers are amongst the top five cancer-
types for incidence and mortality worldwide. New Zealand, along with Australia, leads 
the world in terms of colorectal cancer incidence (1). Furthermore, gastric and 
colorectal cancers are important drivers of the ethnic disparities in the cancer-associated 
morbidity and mortality rates seen in this country (3, 4). Therefore, there is an urgent 
need to improve the diagnosis and management of gastrointestinal cancers.  
 
Examination of ctDNA has the potential to revolutionise the way in which cancers are 
tracked and treated. Serial surveillance of ctDNA has shown promise in tracking 
treatment response and identifying signs of relapse earlier than conventional 
surveillance methods, such as imaging studies and plasma protein biomarkers (62, 68, 
70, 71). The application of ctDNA to the management of gastrointestinal cancers has 
been extensively investigated (62, 68, 75, 81, 82, 85-87, 91, 93, 95). A study conducted 
in the Cancer Genetics Laboratory successfully implemented targeted NGS to identify 
and monitor pathogenic mutations in the plasma of colorectal patients being treated 
with chemotherapy (62). This study relied on tissue sequencing, a common method of 
identifying pathogenic mutations, which is subject to sampling biases arising due to the 
extensive heterogeneity of tumour tissue (51). Direct plasma sequencing has theoretical 
advantages over tissue sequencing in that ctDNA more accurately represents the full 
extent of tumour heterogeneity than a single tissue biopsy (51, 56-58).  Compared to 
tissue sequencing, there is a lack of documented evidence outlining the ability of 
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plasma sequencing to identify pathogenic mutations for the purposes of ctDNA 
surveillance (51).  
 
Research conducted for this thesis investigated the application of ctDNA to the 
management of gastric and colorectal cancers. Firstly, a targeted next generation 
sequencing panel was designed to identify pathogenic mutations directly from plasma 
of patients with gastric and colorectal cancers. This panel was distinct from commercial 
sequencing panels in that it prioritised sequencing depth over breadth to maximise the 
likely sensitivity of mutation detection by sequencing. Secondly, the criteria of 
selecting ctDNA biomarkers was also investigated in colorectal cancers – comparing 
the performance of mutations in tumour suppressor genes and oncogenes in their ability 
to track colorectal tumour dynamics.   
 
6.1 Plasma Sequencing Using the GI Cancer Panel  
Direct plasma sequencing poses unique challenges that were apparently overcome by 
the GI cancer panel. The panel was designed to prioritise sequencing depth over 
genomic breadth by limiting the number of target genes to 21. These targets were 
selected by a manual curation incorporating both quantitative assessments of gastric 
and colorectal sequencing datasets, and a qualitative assessment of candidate genes by a 
cross-reference analysis. In the qualitative cross-reference analysis, various factors such 
as ethnic mutation profiles and biomarkers of metastatic dissemination were considered 
– resulting in a robust panel design able to capture a wide range of gastrointestinal 
cancers. Such a robust design would not have been achieved if solely quantitative 
assessments of sequencing datasets were employed. 
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When tested on gastric and colorectal samples, the GI cancer panel displayed a high 
analytical sensitivity. Rare pathogenic mutations, at frequencies as low as 0.5%, were 
detected in the plasma of both colorectal cancer patients and eight of the ten gastric 
cancer patients. Other commercially available targeted sequencing panels which query 
larger regions of the genome require higher sequencing capacity to reach the depths 
capable of identifying mutations at such low frequencies (51, 127). This suggests that 
the GI cancer panel may be a more cost-effective alternative to such panels, whilst not 
sacrificing analytical sensitivity. 
 
Direct plasma sequencing using the GI cancer panel performed comparably to the FFPE 
sequencing. Of the 14 pathogenic mutations identified in the two colorectal cancer 
patients, 11 were identified in FFPE tissue and ten were identified in plasma, with 
seven observed in both. Dilution of ctDNA by gDNA poses a challenge for detecting 
rare variants in plasma – as higher sequencing depths are required to detect these 
variants in plasma than FFPE (51). However, the ability of ctDNA to capture a wider 
breadth of spatial and temporal tumour heterogeneity than single tissue biopsies makes 
it the preferred sequencing approach – providing high analytical sensitivities can be 
achieved (51, 56-58).  
 
Whilst the 21 genes included in the panel are good markers of GI cancers, identification 
of mutations in these genes is not specific to a gastrointestinal malignancy. These genes 
are frequently mutated in several other types of cancer and other benign conditions such 
as clonal haematopoiesis of indeterminate potential (72, 73). Therefore, the GI cancer 
panel does not harbour the specificity required to be used as a primary diagnostic test, 
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although it could be considered downstream of other screening tests, such as faecal 
occult blood testing (128).  
 
One limitation of the panel is the inability to detect other types of genetic aberrations. 
Large scale copy number variations, as seen in CIN tumours, and aberrant methylation 
patterns, as seen in many MSI tumours, are not able to be detected with the current 
panel design. Whilst targeted sequencing has successfully identified pathogenic 
mutations at frequencies as low as 0.5% in this study, there is a limit to its sensitivity. 
Low-burden disease states pose the largest challenge to targeted sequencing approaches 
due to the low input and random sampling of ctDNA in plasma samples. In these 
instances, WGS approaches have a higher probability of detecting more pathogenic 
mutations due to interrogation of a wider breadth of the tumour genome (71). 
Therefore, alternatives to targeted sequencing need to be explored to capture low-
burden cancers.  
 
A second limitation of the GI cancer panel arises not as a fault of the panel itself, but 
rather the nature of direct plasma sequencing. Whilst plasma sequencing is not subject 
to the biases introduced by tissue biopsies, putative pathogenic mutations identified in 
plasma using NGS cannot be readily validated by independent methods such as 
dideoxy-sequencing; plasma ctDNA is not found at high enough quantities for this 
technology to work. As such, trust must be placed in the variant calling methods, 





In summary, this pilot study demonstrated the feasibility of direct plasma sequencing to 
detect pathogenic mutations in gastric and colorectal cancers. A larger sample size is 
required to determine the full capabilities and limitations of the GI cancer panel 
however, this preliminary data shows promise.   
 
6.2 ctDNA Quantification Using ddPCR Assays  
ddPCR mutation assays are common methods for quantifying ctDNA to monitor the 
tumour burden during treatment (62, 68, 75, 81, 82, 85-87, 91, 93, 95). However, 
careful consideration is required when selecting mutations for follow-up due to 
dynamic changes in the cancer genome throughout treatment courses. Due to their early 
occurrence in colorectal carcinogenesis, tumour suppressor mutations in genes such as 
APC and TP53 are thought to reflect colorectal tumour dynamics more accurately than 
later oncogenic mutations (17, 29). To test this, six colorectal cancer patients had a 
tumour suppressor and oncogenic mutation tracked in their plasma throughout 
treatment with chemotherapy.  
 
No immediate conclusion could be made on which type of mutation better reflects 
tumour dynamics due to the small sample size of the study. However, this study 
demonstrated the need to track multiple mutations to better characterise the tumour 
burden. Multiple-locus assays are less prone to mispresenting tumour dynamics than 
single-loci assays due to their characterisation of a wider breadth of the tumour 
genomic landscape. This also provides the opportunity to monitor cancer subclones, as 
was demonstrated in this study, which has significant clinical applications such as the 
early identification of treatment resistance mechanisms (51). In addition to monitoring 
105 
 
multiple loci, monitoring variants that belong to different treatment pathways may also 
be necessary. In the future, guidelines on biomarker selection may be required to 
standardise serial monitoring of ctDNA using ddPCR assays.  
 
6.3 Recommendations and Future Direction  
Research conducted in this study has highlighted the strengths and weaknesses of 
mutation-based ctDNA analyses – from pre-analytical variables such as blood 
collection and plasma separation through to ctDNA monitoring by ddPCR assays. 
These findings can be translated into two main recommendations for the 
implementation of ctDNA technology into the healthcare system.  
 
Firstly, there needs to be standardisation of the working protocols used to analyse 
ctDNA. Currently, there is extensive variability in the methods implemented to quantify 
and monitor ctDNA. Pre-analytical variables such as blood collection, plasma 
separation, ctDNA extraction, and sample storage have shown to greatly impact ctDNA 
yields, yet there is still an alarming lack of consensus on the optimal pre-analytical 
variables to ensure high quality samples (123). This variability extends into analytical 
variables such as sequencing platforms and approaches. There is evidence to suggest 
targeted approaches are less sensitive than whole genome sequencing in detecting low 
burden disease found in early staged and minimally residual cancers (71). Furthermore, 
epigenomic analyses, such as methylation and DNA fragmentation profiling, are being 
investigated as alternatives to the aforementioned genomic approaches to monitoring 
ctDNA (51). However, this doesn’t appear to be of concern for GI cancers as ctDNA 
analyses frequently identify good ctDNA biomarkers – as was found in this project (62, 
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68, 77-79, 91, 92). Nevertheless, there needs to be continued application of ctDNA 
technologies to various cancer types and stages to determine the optimal methods of 
ctDNA assessment. These methods will likely vary between applications. For example, 
targeted sequencing approaches may be sufficient to identify pathogenic mutations in 
patients with advanced disease, however more sensitive fragmentation analyses may be 
required to diagnose early-stage cancers with ctDNA (129). This extent of 
standardisation is required to make ctDNA technologies more easily implemented.   
 
Secondly, there needs to be significant investment to build the infrastructure capable of 
delivering ctDNA technologies to communities in New Zealand and around the world. 
Due to its quick, minimally invasive nature, and ability to be repeated at serial 
timepoints throughout a disease course, ctDNA has the potential to greatly improve 
cancer survival by better informing therapeutic decisions. Furthermore, ctDNA may be 
used to address cancer inequities and barriers to accessing care in New Zealand. The 
New Zealand Cancer Action Plan 2019-2029 (Te Mahere mō te Mate Pukupuku o 
Aotearoa 2019-2029) is comprised of four main outcomes (130). ctDNA may be used 
to address outcome 2, “New Zealanders experience equitable cancer outcomes,” and 
outcome 4, “New Zealanders have better cancer survival, supportive care, and end-of-
life care”. For outcome 2, ctDNA technologies may be delivered in community-based 
programmes targeted to groups with poor outcomes and high barriers to accessing care, 
such as Māori, Pacific, and rural communities. For outcome 4, ctDNA technologies 
may be implemented in cancer surveillance guidelines to improve the survival and 
supportive care of New Zealanders with cancer. ctDNA technologies have the potential 
to revolutionise the way in which cancers are diagnosed and managed. Action must be 




6.4 Conclusion  
The results presented in this study has generated evidence supporting the 
implementation of ctDNA technologies into the healthcare system. All three aims have 
been successfully achieved. Firstly, a targeted DNA sequencing panel for gastric and 
colorectal cancers was designed. Secondly, this panel was used to successfully identify 
pathogenic mutations in the plasma of gastric and colorectal cancer patients. Finally, 
tumour suppressor and oncogenic mutations were monitored in plasma to track changes 
in colorectal tumour burden during treatment. Action must now be taken by health 
leaders in New Zealand and around the world to implement this revolutionary 
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CHAPTER 8: APPENDICES 
Appendix 1: R Script for Pathogenic Dataset 
Load in COSMICstomach: v91 “COSMIC Complete Mutation Data (Targeted Screens)” filtered for those 
with “stomach” as the primary site 
COSMICstomach<-read.csv("V91_38_TARGETEDSCREENMUTANT.csv", header = TRUE) 
 
#Make a column with simple gene names (i.e. transcript IDs removed ) 
simple.gene.names<-as.character(COSMICstomach[,1]) 
simple.gene.names<-gsub("_ENST0[0-9A-Z]*", "", simple.gene.names) 
COSMICstomach$simple.name<-simple.gene.names 
 




#Exclude squamous cell carcinoma samples 
COSMICstomach<-COSMICstomach[COSMICstomach$HISTOLOGY_SUBTYPE_1 != "squamous_
cell_carcinoma",] 
Create a dataset with only pathogenic FATHMM predictions: 
CSpathogenic<-COSMICstomach[COSMICstomach$FATHMM_PREDICTION == "PATHOGENIC",
] 
Count the number of unique pathogenic samples: 
CSpathogenicsamples<-length(unique(sort(CSpathogenic$SAMPLE_ID))) 
Make a list of pathogenic genes: 
CSpathogenicgenes<-unique(sort(CSpathogenic$simple.name)) 
Count the number of samples for each pathogenic gene: 
CSpathogenicoccurrences<-vector() 
 
for(i in 1:length(CSpathogenicgenes)){ 
  genes<-CSpathogenicgenes[i] 
  CSpathogenicoccurrences[i]<-length(unique(sort(CSpathogenic[CSpathogenic$s
imple.name == genes, "SAMPLE_ID"]))) 
} 
Calculate the frequency of pathogenic mutations in each gene, in the pathogenic dataset: 






Appendix 2: Cross-Reference Analysis Studies 
Supplementary Table 1. Details of the 20 published gastric cancer sequencing studies used in the cross-reference analysis.  
Authors Year Title Sample Types 





Gene List  
Notes 
Cai et al 2019 
Mutational Landscape of 
Gastric Cancer and 
Clinical Application of 
Genomic Profiling Based 
on Targeted Next-
Generation Sequencing 
Tumour tissue and matched 
blood samples from 153 
gastric cancer patients 
Targeted sequencing of 
tumour tissue and PBMCs 
APC, ATM, BRAF, 
BRCA2, CDH1, 
FBXW7, MTOR, 





Molecular Analysis of 
Gastric Cancer Identifies 
Subtypes Associated with 
Distinct Clinical Outcomes 
277 tumour tissue and 14 
matched blood samples 
WGS and targeted re-









Dulak et al  2013 
Exome and Whole-
Genome Sequencing of 
Esophageal 
Adenocarcinoma Identifies 




adenocarcinoma tumour and 
matched normal tissue 
samples 




This study sequenced on 
oesophageal 
adenocarcinomas 
Hu et al 2016 
Genomic Landscape of 
Somatic Alterations in 
Esophageal Squamous Cell 
Carcinoma and Gastric 
Cancer 
Tumour tissue and matched 
blood samples from 4 
patients with oesophageal 
squamous cell carcinoma, 7 
patients with gastric cardia 
adenocarcinoma, and 4 
patients with gastric non-
cardia adenocarcinoma 










Authors Year Title Sample Types 





Gene List  
Notes 
Jia et al 2017 
Discordance of Somatic 
Mutations Between Asian 
and Caucasian Patient 
Populations with Gastric 
Cancer 
Sequencing data from 473 
gastric cancer patients –
accessed from online 
databases and previous 
sequencing studies 





PTEN, SMAD4, TP53 
Rates of APC, ARID1A, 
KMT2A, PIK3CA, and 
PTEN mutations differed 
significantly between 
Asian and Caucasian 
patients  
Kato et al  2018 
Analysis of Circulating 
Tumour DNA and Clinical 









Targeted sequencing of 
ctDNA and PBMCs 











Leal et al 2017 
White Blood Cell and Cell-
Free DNA Analyses for 
Detection of Residual 
Disease in Gastric Cancer 
Blood samples from 50 
patients with resectable 
gastric cancer  
Targeted sequencing of 
ctDNA and PBMCs 















Junction and Gastric 
Carcinomas 
Tumour tissue samples from 
92 gastroesophageal 
junction adenocarcinomas 
and 75 gastric 
adenocarcinomas 
 
Targeted sequencing of 
tumour tissue 






PTEN, SMAD4, TP53 
BRAF and FBXW7 were 
only found in gastric 
cancers. PTEN was only 
found in gastroesophageal 
junction cancers  
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Authors Year Title Sample Types 










Universal Patterns of 
Selection in Cancer and 
Somatic Tissues 
Tumour and matched 
normal tissue samples from 
360 stomach 
adenocarcinomas  
WES of tumour and matched 







Listed genes are those 
containing non-
synonymous substitutions 
or indels under significant 
positive selection in 







Gastric Cancer in the 
Japanese Population 
49 tumour tissue samples 
from patients with 
differentiated-type non-
invasive gastric cancer 
WES or targeted sequencing 






Oh et al 2018 
Clinical and Genomic 
Landscape of Gastric 
Cancer with a 
Mesenchymal Phenotype 
Sequencing data from 257 
gastric cancer patient – 
accessed from online 
databases  
WES of tumour tissue 
FAT4, LRP1B, 
PIK3CA, TP53, TTN 
 
Pan et al 2018 
Landscape of Somatic 
Mutations in Gastric 
Cancer Assessed Using 
Next-Generation 
Sequencing Analysis 
45 tumour tissue samples 
from patients with gastric 
adenocarcinomas 
Targeted sequencing of 
tumour tissue 








Salem et al  2018 
Comparative Molecular 
Analyses of Esophageal 




Tumour tissue samples from 
1, 849 gastroesophageal 
cancers – 157 oesophageal 
squamous cell carcinomas, 
599 oesophageal 
adenocarcinomas, and 1,093 
gastric adenocarcinomas 
Targeted sequencing of 
tumour tissue 









ERBB2, APC, and RNF43 
mutations were not found 
in any oesophageal 
squamous cell carcinomas. 
CDH1 mutations were 




Authors Year Title Sample Types 












Characterisation of Gastric 
Adenocarcinoma 
215 non-hypermutated 
tumour tissue samples  







Genes mutated in 
hypermutated samples 
were excluded 




Profiling Identify New 
Driver Mutations in 
Gastric Cancer 
100 tumour and matched 
normal tissue samples from 
patients with gastric 
adenocarcinoma 













of Synchronous Multiple 
Gastric Cancer 
33 tumour tissue samples 
from 16 patients with 
multiple gastric cancer - 9 
samples were diagnosed at 
the gastroesophageal 
junction.   









Multiplex Profiling of 
Peritoneal Metastases from 
Gastric Adenocarcinoma 
Identified Novel Targets 
and Molecular Subtypes 
that Predict Treatment 
Response 
Tumour tissue samples from 
34 gastric adenocarcinoma 
patients with peritoneal 
metastases 













of Cancer Genes Identified 
Key Molecular Biomarkers 
in Stomach 
Adenocarcinoma 
Sequencing data from 387 
stomach adenocarcinoma 
samples - accessed from 
online databases.  
Prediction of driver gene 
mutations in the TCGA 










Authors Year Title Sample Types 





Gene List  
Notes 
Wong et al 2014 
Genomic Landscape and 




Tumour tissue and matched 
blood samples from 49 
patients with gastric cancer 





Vošmik et al  2018 
HPV Status and Mutation 
Analysis Using 
Multiparallel Sequencing 
in Distal Oesophageal and 
Gastro-Oesophageal 
Junction Adenocarcinomas 
56 tumour tissue samples 















Appendix 3: Bioanalyzer Traces of DNA Samples  
Supplementary Figure 1. Bioanalyzer traces of colorectal and gastric DNA samples. A. 
FFPE (FF043 and FF047) and ctDNA (M043C1, M043C2, M047C1, and M047C2) samples 
























Supplementary Figure 2. Bioanalyzer traces of DNA sequencing libraries. 
A. Sequencing libraries of two FFPE (FF043 and FF047) and four ctDNA 
(M043C1, M043C2, M047C1, and M047C2) samples from two patients with 
colorectal cancer (M043 and M047). B. Sequencing libraries ctDNA samples 
from ten gastric cancer patients. 
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Appendix 5: Pathogenic Mutations Identified in Gastric ctDNA Samples  
 
  
GC101 Run 1 
Reads: 4,661,410 
Lower Detection Limit: 1% 
GC101 Run 2 
Reads: 9,137,986 
Lower Detection Limit: 1% 
GC101 Run 3 
Reads: 13,385,358 
Lower Detection Limit: 1% 
GC101 Run 4 
Reads: 17,358,734 
Lower Detection Limit: 0.5% 
   
ATM c.7242delA 
Frequency: 0.566572238% 
Type: Non-Synonymous Deletion 
Total Counts: 12 
Singleton UMI Counts: 5 
Big UMI Counts: 7 
Coverage: 2118 
   
BRAF c.1208delC 
Frequency: 0.612155662%  
Type: Non-Synonymous Deletion 
Total Counts: 14 
Singleton UMI Counts: 12 
Big UMI Counts: 2 
Coverage: 2287 
Supplementary Table 2. Pathogenic mutations identified in the ctDNA of GC101. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. UMI: unique molecular index.  
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Supplementary Table 3. Pathogenic mutations identified in the ctDNA of GC102. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. MNV: multi-nucleotide variant; SNV: single-nucleotide 
variant; UMI: unique molecular index.  
  GC102 Run 1 
Reads: 3,575,712 
Lower Detection Limit: 1% 
GC102 Run 2 
Reads: 7,030,546 
Lower Detection Limit: 1% 
GC102 Run 3 
Reads: 10,291,238 
Lower Detection Limit: 1% 
GC102 Run 4 
Reads: 13,350,832 
Lower Detection Limit: 0.5% 
ATM c.6689_6690delTTinsGA 
Frequency: 1.147227533% 
Type: Non-Synonymous MNV 
Total Counts: 6 
Singleton UMI Counts: 6 




Type: Non-Synonymous MNV 
Total Counts: 10 
Singleton UMI Counts: 9 




Type: Non-Synonymous MNV 
Total Counts: 12 
Singleton UMI Counts: 12 
Big UMI Counts: 2 
Coverage: 847 
ATM c.6689_6690delTTinsGA 
Frequency: 1.405405405%  
Type: Non-Synonymous MNV 
Total Counts: 13 
Singleton UMI Counts: 10 
Big UMI Counts: 3 
Coverage: 925 
  ARID1A c.1752_1753delTCinsCT 
Frequency: 1.00% 
Type: Non-Synonymous MNV 
Total Counts: 8 
Singleton UMI Counts: 7 




Type: Non-Synonymous MNV 
Total Counts: 11 
Singleton UMI Counts: 8 
Big UMI Counts: 3 
Coverage: 889 
  ERBB2 c.2588A>T 
Frequency: 1.615508885% 
Type: Non-Synonymous SNV 
Total Counts: 10 
Singleton UMI Counts: 9  




Type: Non-Synonymous SNV 
Total Counts: 12 
Singleton UMI Counts: 11 




  GC102 Run 1 
Reads: 3,575,712 
Lower Detection Limit: 1% 
GC102 Run 2 
Reads: 7,030,546 
Lower Detection Limit: 1% 
GC102 Run 3 
Reads: 10,291,238 
Lower Detection Limit: 1% 
GC102 Run 4 
Reads: 13,350,832 
Lower Detection Limit: 0.5% 
  ERBB3 c.969T>A 
Frequency: 1.884057971% 
Type: Non-Synonymous SNV 
Total Counts: 13 
Singleton UMI Counts: 11 




Type: Non-Synonymous SNV 
Total Counts: 14 
Singleton UMI Counts: 9 
Big UMI Counts: 5 
Coverage: 759 
   BRCA2 c.5290_5291delTC 
Frequency: 0.78125% 
Type: Non-Synonymous Deletion  
Total Counts: 3 
Singleton UMI Counts: 1 
Big UMI Counts: 2 
Coverage: 384 
   CDKN2A c.207_208delGCinsCT 
Frequency: 1.055806938% 
Type: Non-Synonymous MNV 
Total Counts: 7 
Singleton UMI Counts: 7 
Big UMI Counts: 0 
Coverage: 663 
   ERBB4 c.119_120delCT 
Frequency: 0.611246944% 
Type: Non-Synonymous Deletion  
Total Counts: 5 
Singleton UMI Counts: 5 




  GC102 Run 1 
Reads: 3,575,712 
Lower Detection Limit: 1% 
GC102 Run 2 
Reads: 7,030,546 
Lower Detection Limit: 1% 
GC102 Run 3 
Reads: 10,291,238 
Lower Detection Limit: 1% 
GC102 Run 4 
Reads: 13,350,832 
Lower Detection Limit: 0.5% 
   ERBB4 c.2237T>G 
Frequency: 1.156069364% 
Type: Non-Synonymous SNV 
Total Counts: 8 
Singleton UMI Counts: 8 
Big UMI Counts: 0 
Coverage: 692 
   PIK3CA c.1145G>A 
Frequency: 2.282453638% 
Type: Non-Synonymous SNV 
Total Counts: 16 
Singleton UMI Counts: 14 







Supplementary Table 4. Pathogenic mutations identified in the ctDNA of GC103. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. UMI: unique molecular index. 
 
 
Supplementary Table 5. Pathogenic mutations identified in the ctDNA of GC104. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. UMI: unique molecular index. 
GC104 Run 1 
Reads: 4,407,962 
Lower Detection Limit: 1% 
GC104 Run 2 
Reads: 8,647,772 
Lower Detection Limit: 1% 
GC104 Run 3 
Reads: 12,673,554 
Lower Detection Limit: 1% 
GC104 Run 4 
Reads: 16,465,616 
Lower Detection Limit: 0.5% 
- - - - 
 
GC103 Run 1 
Reads: 3,488,454 
Lower Detection Limit: 1% 
GC103 Run 2 
Reads: 6,857,298 
Lower Detection Limit: 1% 
GC103 Run 3 
Reads: 10,078,270 
Lower Detection Limit: 1% 
GC103 Run 4 
Reads: 13,126,956 
Lower Detection Limit: 0.5% 
   BRCA2 c.8021delA 
Frequency: 0.607164542% 
Type: Synonymous Deletion  
Varsome: Pathogenic 
COSMIC: -  
Total Counts: 10 
Singleton UMI Counts: 9 




Supplementary Table 6. Pathogenic mutations identified in the ctDNA of GC105. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. UMI: unique molecular index. 
 
  
GC105 Run 1 
Reads: 3,968,146 
Lower Detection Limit: 1% 
GC105 Run 2 
Reads: 7,787,242 
Lower Detection Limit: 1% 
GC105 Run 3 
Reads: 11,424,086 
Lower Detection Limit: 1% 
GC105 Run 4 
Reads: 14,876,788 
Lower Detection Limit: 0.5% 
- - - - 
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Supplementary Table 7. Pathogenic mutations identified in the ctDNA of GC106. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. SNV: single-nucleotide variant; UMI: unique molecular 
index. 
GC106 Run 1 
Reads: 3,842,740 
Lower Detection Limit: 1% 
GC106 Run 2 
Reads: 7,583,600 
Lower Detection Limit: 1% 
GC106 Run 3 
Reads: 11,190,350 
Lower Detection Limit: 1% 
GC106 Run 4 
Reads: 14,579,064 
Lower Detection Limit: 0.5% 
ERBB2 c.2588A>C 
Frequency:  1.616161616% 
Type: Non-Synonymous SNV 
Total Counts: 8 
Singleton UMI Counts: 8 
Big UMI Counts: 0 
Coverage: 495 
ERBB2 c.2588A>C 
Frequency: 1.584786054%  
Type: Non-Synonymous SNV 
Total Counts: 10 
Singleton UMI Counts: 8 




Type: Non-Synonymous SNV 
Total Counts: 14 
Singleton UMI Counts: 12 




Type: Non-Synonymous SNV 
Total Counts: 19 
Singleton UMI Counts: 11 




Type: Non-Synonymous Deletion 
Total Counts: 5 
Singleton UMI Counts: 4 
Big UMI Counts: 1 
Coverage: 248 
LRP1B c.7971delG 
Frequency: 1.602564103%  
Type: Non-Synonymous Deletion 
Total Counts: 5 
Singleton UMI Counts: 4 
Big UMI Counts: 1 
Coverage: 312 
LRP1B c.7971delG 
Frequency: 1.424501425%   
Type: Non-Synonymous Deletion 
Total Counts: 5 
Singleton UMI Counts: 4 
Big UMI Counts: 1 
Coverage: 351 
LRP1B c.7971delG 
Frequency: 1.262626263%  
Type: Non-Synonymous Deletion 
Total Counts: 5 
Singleton UMI Counts: 4 
Big UMI Counts: 1 
Coverage: 396 
  ERBB3 c.4018C>T 
Frequency: 1.62412993% 
Type: Non-Synonymous SNV 
Total Counts: 14 
Singleton UMI Counts: 13 




Type: Non-Synonymous SNV 
Total Counts: 15 
Singleton UMI Counts: 13 




GC106 Run 1 
Reads: 3,842,740 
Lower Detection Limit: 1% 
GC106 Run 2 
Reads: 7,583,600 
Lower Detection Limit: 1% 
GC106 Run 3 
Reads: 11,190,350 
Lower Detection Limit: 1% 
GC106 Run 4 
Reads: 14,579,064 
Lower Detection Limit: 0.5% 
   BRCA2 c.8845dupA 
Frequency: 0.564971751% 
Type: Non-Synonymous Insertion 
Total Counts: 3 
Singleton UMI Counts: 2 
Big UMI Counts: 1 
Coverage: 531 
   EGFR c.797delC 
Frequency: 1.081081081%  
Type: Non-Synonymous Deletion  
Total Counts: 12 
Singleton UMI Counts: 11 
Big UMI Counts: 1 
Coverage: 1110 
   KRAS c.483_484delGG 
Frequency: 0.610997963% 
Type: Non-Synonymous Deletion  
Total Counts: 3 
Singleton UMI Counts: 2 
Big UMI Counts: 1 
Coverage: 491 
   LRP1B c.12386_12387delAT 
Frequency: 0.598802395% 
Type: Non-Synonymous Deletion  
Total Counts: 2 
Singleton UMI Counts: 2 






Supplementary Table 8. Pathogenic mutations identified in the ctDNA of GC107. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. SNV: single-nucleotide variant; UMI: unique molecular 
index. 
  
GC107 Run 1 
Reads: 3,630,662 
Lower Detection Limit: 1% 
GC107 Run 2 
Reads: 7,111,030 
Lower Detection Limit: 1% 
GC107 Run 3 
Reads: 10,412,020 
Lower Detection Limit: 1% 
GC107 Run 4 
Reads: 13,521,862 
Lower Detection Limit: 0.5% 
   ERBB2 c.2333C>A 
Frequency: 0.839793282% 
Type: Non-Synonymous SNV 
Total Counts: 13 
Singleton UMI Counts: 12 
Big UMI Counts: 1 
Coverage: 1548 
   ERBB4 c.119_120delCT 
Frequency:  0.58685446% 
Type: Non-Synonymous Deletion  
Total Counts: 5 
Singleton UMI Counts: 5 
Big UMI Counts: 0 
Coverage: 852 
   ERBB4 c.2522A>C 
Frequency: 1.464713715% 
Type: Non-Synonymous SNV 
Total Counts: 11 
Singleton UMI Counts: 10  




Supplementary Table 9. Pathogenic mutations identified in the ctDNA of GC108. Four Miseq sequencing runs were performed in series. Successive runs 
were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. SNV: single-nucleotide variant; MNV: multi-nucleotide 
variant; UMI: unique molecular index.  
  
GC108 Run 1 
Reads: 3,211,000 
Lower Detection Limit: 1% 
GC108 Run 2 
Reads: 6,279,194 
Lower Detection Limit: 1% 
GC108 Run 3 
Reads: 9,174,668 
Lower Detection Limit: 1% 
GC108 Run 4 
Reads: 11,886,532 
Lower Detection Limit: 0.5% 
TP53 c.723A>T 
Frequency: 1.456953642% 
Type: Non-Synonymous SNV 
Total Counts: 11 
Singleton UMI Counts: 7 
Big UMI Counts: 4 
Coverage: 755 
TP53 c.723A>T 
Frequency: 1.237113402%  
Type: Non-Synonymous SNV 
Total Counts: 12 
Singleton UMI Counts: 3 
Big UMI Counts: 9 
Coverage: 970 
TP53 c.723A>T 
Frequency: 1.172227232%  
Type: Non-Synonymous SNV 
Total Counts: 13 
Singleton UMI Counts: 1 
Big UMI Counts: 12 
Coverage: 1109 
TP53 c.723A>T 
Frequency: 1.144726083%   
Type: Non-Synonymous SNV 
Total Counts: 14 
Singleton UMI Counts: 1 
Big UMI Counts: 13 
Coverage: 1223 
   ERBB3 c.2540_2541delAGinsCT 
Frequency: 0.858895706% 
Type: Non-Synonymous MNV 
Total Counts: 7 
Singleton UMI Counts: 6 
Big UMI Counts: 1 
Coverage: 815 
   TP53 c.763A>C 
Frequency: 0.716479017% 
Type: Non-Synonymous SNV 
Total Counts: 7 
Singleton UMI Counts: 6 




Supplementary Table 10. Pathogenic mutations identified in the ctDNA of GC201. Four Miseq sequencing runs were performed in series. Successive 
runs were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. SNV: single-nucleotide variant; UMI: unique molecular 
index. 
GC201 Run 1 
Reads: 3,280,842 
Lower Detection Limit: 1% 
GC201 Run 2 
Reads: 6,419,090 
Lower Detection Limit: 1% 
GC201 Run 3 
Reads: 9,419,906 
Lower Detection Limit: 1% 
GC201 Run 4  
Reads: 12,233,594 
Lower Detection Limit: 0.5% 
BRAF c.1208delC 
Frequency: 1.12704918% 
Type: Non-Synonymous Deletion  
Total Counts: 11 
Singleton UMI Counts: 11 





Type: Non-Synonymous Deletion  
Total Counts: 12 
Singleton UMI Counts: 10 




Type: Non-Synonymous SNV 
Total Counts: 10 
Singleton UMI Counts: 6 




Type: Non-Synonymous SNV 
Total Counts: 18 
Singleton UMI Counts: 9 




Type: Non-Synonymous SNV 
Total Counts: 22 
Singleton UMI Counts: 10 
Big UMI Counts: 12 
Coverage: 1612 
LRP1B c.3981A>C 
Frequency: 1.502504174%  
Type: Non-Synonymous SNV 
Total Counts: 27 
Singleton UMI Counts: 13 
Big UMI Counts: 14 
Coverage: 1797 
TP53 c.733G>A 
Frequency: 2.842809365%  
Type: Non-Synonymous SNV 
Total Counts: 34 
Singleton UMI Counts: 23 




Type: Non-Synonymous SNV 
Total Counts: 53 
Singleton UMI Counts: 24 




Type: Non-Synonymous SNV 
Total Counts: 65 
Singleton UMI Counts: 26 
Big UMI Counts: 39 
Coverage: 2196 
TP53 c.733G>A 
Frequency: 3.021641486%  
Type: Non-Synonymous SNV 
Total Counts: 74 
Singleton UMI Counts: 30 




GC201 Run 1 
Reads: 3,280,842 
Lower Detection Limit: 1% 
GC201 Run 2 
Reads: 6,419,090 
Lower Detection Limit: 1% 
GC201 Run 3 
Reads: 9,419,906 
Lower Detection Limit: 1% 
GC201 Run 4  
Reads: 12,233,594 
Lower Detection Limit: 0.5% 
 CTNNB1 c.1760G>A 
Frequency: 1.064537591% 
Type: Non-Synonymous SNV 
Total Counts: 16 
Singleton UMI Counts: 13 
Big UMI Counts: 3 
Coverage: 1503 
CTNNB1 c.1760G>A 
Frequency: 1.079330815%  
Type: Non-Synonymous SNV 
Total Counts: 20 
Singleton UMI Counts: 16 
Big UMI Counts: 4 
Coverage: 1853 
CTNNB1 c.1760G>A 
Frequency: 0.959692898%   
Type: Non-Synonymous SNV 
Total Counts: 20  
Singleton UMI Counts: 11 
Big UMI Counts: 9 
Coverage: 2084 
  BRCA2 c.8940delA 
Frequency: 1.206140351%  
Type: Non-Synonymous Deletion  
Total Counts: 11 
Singleton UMI Counts: 10 
Big UMI Counts: 1 
Coverage: 912 
BRCA2 c.8940delA 
Frequency: 0.8712487899322362%  
Type: Non-Synonymous Deletion  
Total Counts: 9 
Singleton UMI Counts: 8 
Big UMI Counts: 1 
Coverage: 1033 
   ERBB2 c.1601+2_1602del 
Frequency: 0.740009867%  
Type: Non-Synonymous Deletion  
Total Counts: 30 
Singleton UMI Counts: 14 






Supplementary Table 11. Pathogenic mutations identified in the ctDNA of GC202. Four Miseq sequencing runs were performed in series. Successive 
runs were processed with previous runs – resulting in the collation of sequencing reads with each new run. Pathogenic mutations were identified after the 
completion of each run. Variants were called down to a frequency of 1% in the first three runs and 0.5% in the fourth run. The frequency, type, total UMI 
counts, singleton UMI counts, big UMI counts, and coverage are reported for each identified variant. SNV: single nucleotide variant; UMI: unique molecular 
index 
GC202 Run 1 
Reads: 2,730,806 
Lower Detection Limit: 1% 
GC202 Run 2 
Reads: 5,339,462 
Lower Detection Limit: 1% 
GC202 Run 3 
Reads: 7,798,802 
Lower Detection Limit: 1% 
GC202 Run 4 
Reads: 10,107,248 
Lower Detection Limit: 0.5% 
CDH1 c.932dupA 
Frequency: 10.58282209% 
Type: Non-Synonymous Insertion 
Total Counts: 69 
Singleton UMI Counts: 45 




Type: Non-Synonymous Insertion 
Total Counts: 118 
Singleton UMI Counts: 59  




Type: Non-Synonymous Insertion 
Total Counts: 148 
Singleton UMI Counts: 70  




Type: Non-Synonymous Insertion 
Total Counts: 172 
Singleton UMI Counts: 73 




Type: Non-Synonymous SNV 
Total Counts: 120 
Singleton UMI Counts: 91 




Type: Non-Synonymous SNV 
Total Counts: 170  
Singleton UMI Counts: 103 




Type: Non-Synonymous SNV 
Total Counts: 199 
Singleton UMI Counts: 90  




Type: Non-Synonymous SNV 
Total Counts: 215 
Singleton UMI Counts: 82 
Big UMI Counts: 133 
Coverage: 1160 
   ATM c.7242delA 
Frequency: 0.62745098% 
Type: Synonymous Deletion  
Total Counts: 8 
Singleton UMI Counts: 1 




GC202 Run 1 
Reads: 2,730,806 
Lower Detection Limit: 1% 
GC202 Run 2 
Reads: 5,339,462 
Lower Detection Limit: 1% 
GC202 Run 3 
Reads: 7,798,802 
Lower Detection Limit: 1% 
GC202 Run 4 
Reads: 10,107,248 
Lower Detection Limit: 0.5% 
   PIK3CA c.3140A>G 
Frequency: 1.013758146% 
Type: Non-Synonymous SNV 
Total Counts: 14 
Singleton UMI Counts: 7 
Big UMI Counts: 7 
Coverage: 1381  
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Appendix 6: Comparison of Variant Calling by the GeneGlobe 
Data Analysis Centre and CLC Genomics Workbench 
Supplementary Table 12. Comparison of pathogenic mutations identified by the 
GeneGlobe Portal and the CLC Genomics Workbench in colorectal cancer FFPE and 
ctDNA samples. SNV: single nucleotide variant.  




Type: Non-Synonymous SNV  
APC c.3340C>T 
Frequency: 33.33333333% 
Type: Non-Synonymous SNV  
APC c.3956delC 
Frequency: 31.69492% 
Type: Non-Synonymous Deletion   
APC c.3956delC 
Frequency: 31.63751987%  
Type: Non-Synonymous Deletion 
TP53 c.572delC 
Frequency: 58.55962% 
Type: Non-Synonymous Deletion   
TP53 c.572delC 
Frequency: 59.93377483% 
Type: Non-Synonymous Deletion  
 SMAD4 c.217delAinsCT 
Frequency: 4.540295119% 
Type: Non-Synonymous Replacement  
 APC c.905G>A 
Frequency: 3.495994173% 
Type: Non-Synonymous SNV  
 BRCA2 c.9097delA 
Frequency: 3.024390244% 
Type: Non-Synonymous SNV  
 BRCA2 c.5073delA 
Frequency: 1.251956182% 




Type: Non-Synonymous SNV 
APC c.646C>T 
Frequency: 25.35377358%  
Type: Non-Synonymous SNV 
APC c.4099C>T 
Frequency: 23.6014% 
Type: Non-Synonymous SNV  
APC c.4099C>T 
Frequency: 23.359375% 
Type: Non-Synonymous SNV  
 BRCA2 c.9097delA 
Frequency: 2.43804956% 
Type: Non-Synonymous Deletion  
M043C1 
 PIK3CA c.1571G>A 
Frequency: 2.131782946% 




Type: Non-Synonymous SNV  
APC c.3340C>T 
Frequency: 1.654411765% 
Type: Non-Synonymous SNV  
TP53 c.572delC 
Frequency: 2.3845% 
Type: Non-Synonymous Deletion   
TP53 c.572delC 
Frequency: 2.577319588% 
Type: Non-Synonymous Deletion 
 APC c.3956delC 
Frequency: 1.503759398% 
Type: Non-Synonymous Deletion  
 BRCA2 c.5073delA 
Frequency: 1.023541453% 




Type: Non-Synonymous SNV  
APC c.646C>T 
Frequency: 2.580645161% 
Type: Non-Synonymous SNV 
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Sample GeneGlobe CLC Workbench 
APC c.4099C>T 
Frequency: 3.06122% 
Type: Non-Synonymous SNV  
APC c.4099C>T 
Frequency: 2.167630058%  
Type: Non-Synonymous SNV  
TP53 c.524G>A 
Frequency: 9.42249% 
Type: Non-Synonymous SNV  
TP53 c.524G>A 
Frequency: 9.827586207% 
Type: Non-Synonymous SNV  
 BRCA2 c.1813delA 
Frequency: 2.096436059%  
Type: Non-Synonymous Deletion  
 ERBB3 c.2617-1dupG 
Frequency: 1.397205589%  




Type: Non-Synonymous SNV  
APC c.4099C>T 
Frequency: 1.283316881% 
Type: Non-Synonymous SNV  
TP53 c.524G>A 
Frequency: 6.65188% 
Type: Non-Synonymous SNV  
TP53 c.524G>A 
Frequency: 5.952380952% 




Appendix 7: Sequencing and PCR Errors Incorrectly Called by 
the CLC Genomics Workbench   
Supplementary Table 13. Variants identified in both gastric ctDNA and a normal gDNA 
control by the CLC Genomics Workbench. Variants identified in the gDNA control are 



































Supplementary Figure 3. Droplet fluorescence amplitude of APC c.4308delT 
measured in the plasma of M006 by ddPCR. A. Droplet fluorescence of mutant 
probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 4. Droplet fluorescence amplitude of KRAS c.436G>A 
measured in the plasma of M006 by ddPCR. A. Droplet fluorescence of mutant 








Supplementary Figure 6. Droplet fluorescence amplitude of BRAF c.1799T>A 
measured in the plasma of M018 by ddPCR. A. Droplet fluorescence of mutant 
probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 5. Droplet fluorescence amplitude of TP53 c.586C>T 
measured in the plasma of M018 by ddPCR. A. Droplet fluorescence of mutant 









Supplementary Figure 7. Droplet fluorescence amplitude of BRAF c.1799T>A 
measured in the plasma of M027 by ddPCR. A. Droplet fluorescence of mutant 
probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 8. Droplet fluorescence amplitude of TP53 
c.637C>T measured in the plasma of M027 by ddPCR. A. Droplet 


















Supplementary Figure 9. Droplet fluorescence amplitude of BRAF 
c.1799T>A measured in the plasma of M034 by ddPCR. A. Droplet 
fluorescence of mutant probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 10. Droplet fluorescence amplitude of TP53 
c.514G>T measured in the plasma of M034 by ddPCR. A. Droplet 

















Supplementary Figure 11. Droplet fluorescence amplitude of APC 
c.1495C>T measured in the plasma of M045 by ddPCR. A. Droplet 
fluorescence of mutant probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 12. Droplet fluorescence amplitude of PIK3CA 
c.1624G>A measured in the plasma of M045 by ddPCR. A. Droplet 















Supplementary Figure 13. Droplet fluorescence amplitude of APC 
c.4271delC measured in the plasma of M050 by ddPCR. A. Droplet 
fluorescence of mutant probe. B. Droplet fluorescence of wild-type probe. 
Supplementary Figure 14. Droplet fluorescence amplitude of KRAS c.35G>T 
measured in the plasma of M050 by ddPCR. A. Droplet fluorescence of mutant 
probe. B. Droplet fluorescence of wild-type probe. 
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